Feeds:
Posts
Comments

Archive for the ‘Biological Networks, Gene Regulation and Evolution’ Category

Reporter: Aviva Lev-Ari, PhD, RN

 
 
 
Fluidigm Corporation (NASDAQ: FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets four microfluidic systems, including nine different commercial chips, to leading academic institutions, diagnostic laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. Fluidigm products are marketed for research purposes only (not for diagnostic use).
Fluidigm Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $60 million Public Offering of Common Stock

SOUTH SAN FRANCISCO, CALIFORNIA – August 21, 2012 – Fluidigm Corporation (NASDAQ: FLDM), a supplier of microfluidic systems for growth markets in the life science and agricultural biotechnology industries, today announced that it has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million. The shares include 549,000 shares of common stock sold pursuant to the over-allotment option granted by Fluidigm to the underwriters, which option was exercised in full. The net proceeds from the sale of the shares, after deducting the underwriters’ discounts and commissions and other estimated offering expenses payable by Fluidigm, will be approximately $56.1 million.
Fluidigm currently plans to use the net proceeds from this offering for research and development, commercialization of its products, working capital and other general corporate purposes.
Piper Jaffray & Co. and Cowen and Company, LLC acted as the joint book-running managers for the offering.  Leerink Swann LLC, Oppenheimer & Co. Inc. and Cantor Fitzgerald & Co. acted as the co-managers for the offering.

A shelf registration statement (File No. 333-180550) relating to these securities was filed on April 4, 2012, as amended on May 7, 2012, and declared effective by the Securities and Exchange Commission on May 10, 2012.  A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC on August 16, 2012.  Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com, or from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140). An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering is available on the website of the Securities and Exchange Commission at http://www.sec.gov/.
This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of Fluidigm, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

In order to provide Fluidigm’s investors with an understanding of our current intentions and future prospects, this release may contain statements that are forward-looking.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include our expectations regarding the offering and the use of proceeds from such offering.
Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including market risk and the risks we identify in reports filed with the SEC.
Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the SEC. Fluidigm does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

 
 

The C1™ Single-Cell Auto Prep System is a new approach to single-cell gene expression.

 
For the first time, extract, reverse transcribe, preamplify, and ultimately detect and analyze cell activity using just one technology:

 

  • Resolves individual cells 
  • Easy and intuitive 
  • Cell input to data in less than a day
  • Reduced technical noise for reliable results
  • qPCR profiling of gene expression
 
 
 
 
 

Applications

 

Learn about the advantages of Integrated Fluidic Circuits (IFCs) for your specific application.

Gene Expression
High throughput • Low cost • Compatibility with existing
reagents
a2.pngSingle-Cell Gene Expression
High sample throughput • More results faster • Assay
flexibility
   
a6.pngSNP Genotyping
Higher sample throughput • Outstanding data quality •
Dramatically lower costs
a5.pngTargeted Resequencing
Target enrichment • Sample barcoding for multiplexed
sequencing • Sequencing
library preparation using amplicon tagging
   
a1.pngSample Quantitation
Ability to amplify individual
molecules • Accurately and
reproducibly determine
library concentrations
a4.pngCopy Number Variation
High-resolution CNV studies using digital PCR •
Simple, fast, and reliable workflow • Standard
assays and reagents
 

Research Publications Featuring Fluidigm Products

 

Select from the Following Categories:

Gene Expression

Single-Cell Gene Expression

SNP Genotyping

Targeted Resequencing

Number Variation/Digital Quantification

Other

Gene Expression

 

Single-Cell Gene Expression

 

SNP Genotyping

 

Targeted Resequencing

 

Copy Number Variation/Digital Quantification/Digital PCR

Protein Crystallization

 

Products

Fluidigm develops and distributes life science systems based on our proprietary Integrated Fluidic Circuits (IFCs).  We currently offer the following complete systems and products:

b5.pngBioMark™ HD System
Reproducible results down to
a single cell • Fast PCR enabled •
Collect more data points per
day • Multiple reagents with different sample configurations
Granicus_Right_315.jpgC1™ System
Single-cell precision • Easy to use • Fast—cell input-to-data • All in one—comprehensive • Flexible—expandable
   
b3.pngAccess Array™ System
Target enrichment • Sample
barcoding for multiplexed
sequencing • Sequencing library prep using amplicon tagging
b4.pngEP1™ System
Accelerated workflow • Outstanding data Quality • Efficient high sample throughput SNP Genotyping
   
b2.pngDeltagene™ Assays
High quality—sensitivity and linearity
similar to probe-based assays •
MIQE* compliant—assay primer
sequences provided • Cost savings
—low startup and running costs
b6.pngChips & Kits
192.24 – 192 samples x 24
assays  • 48.48 – 48 samples x 48 assays • 96.96 – 96 samples x 96 assays
   
AA_TS_Primers_Image.jpgTarget-Specific Primers
Custom-designed primer sets •
multiplex capability allows up to 480 amplicons per sample • Amplicon tagging bypasses traditional library preparation
b1.pngSNPtype™ Assays 
Low start-up and running costs • Locus-specific primer sequences provided • Change targets on demand
#
topazproduct.pngOther Products

 

Read Full Post »

Author and Reporter: Anamika Sarkar, Ph.D and Ritu Saxena, Ph.D.

 Cartilage is the tissue lining of the joints and acts as a cushion between the joints. Osteoarthritis, a disease accompanied by severe pain and limitations of functions, is the result of degeneration of cartilage. Currently, such conditions of patients are considered irreversible and treatment options are mainly based on pain management and joint replacement therapy.

Some of these procedures are –  Autologous Chondrocyte Implantation (ACI), Osteochondral Allograft Transplantation, Meniscal Transplantation. In these procedures, healthy cartilage (or meniscus in case of Meniscal Transplantation) are taken either from the patients or deceased donors and transplanted in the damaged joints for cartilage repair. (Please see information regarding cartilage repair, cartilage supplement in sources below).

Harnessing use of regenerative powers of stem cells have been recognized as alternative methods of treatments. Stem cells are the cells that have the capacity to develop into different cell types. They can continue to renew themselves with cell division without being differentiated.  Moreover, with the right stimulus they can also be induced to differentiate into specialized cell types. Thus, with discovery and understanding of right stimuli and its signaling processes, stem cells can serve as a powerful candidate for repair of damaged tissues and organs.

Since, stem cells are precursor of many differentiated cell types, a lot of research is needed to determine the right conditions to direct the stem cell differentiation into the desired cell type for the purpose of treatment. Attempts have been made in the area of regenerative medicine for cartilage regeneration using stem cells. Kafienah et al (2007) bioengineered a three-dimensional cartilage using adult stem cells from the bone marrow of osteoarthritis patients. Although, this method could thus be used for repairing cartilage lesions, however, it needs to be implanted into the joint adding challenges to the development of therapy.

A very interesting study published in the recent issue of the journal Science (Johnson et. al., A Stem Cell-Based Approach to Cartilage Repair, Science, 336, p717,2012) described breakthrough discovery – a small molecule, Kartogenin (KGN), has the capability of promoting chondrocytes (cells which make healthy cartilage) differentiation.

The authors, Johnson et al. showed their finding of KGN as a stimulus for stem cell differentiation to chondrocytes in a systematic fashion. They used high throughput screening of images from 5 primary human stem cells derived from bone marrow in their in-vitro studies. Their results show when cells were treated with 100nM of KGN, they show regeneration of cartilage forming chondrocytes. They supported their finding in animal model using mice model by inducing Osteoarthritis and then treating them with KGN.

In order to make sure that KGN has a direct effect on the signaling of chondrocytes, Johnson et. al., showed activation of some of the key signaling components in the KGN stimulated chondrocytes pathway, using in-vitro studies. They showed that upon activation of cells with KGN, CBFb (core-binding factor β subunit)  translocates into the nucleus and activates signaling components of  RUNX (one of the runt-related transcription factor family member), leaving behind free cytoplasmic binding partner FLNA (Flaming A). They also show strong correlation between CBFb and regeneration of chrondocytes.

Stem cell therapy has uncounted potential for giving better life to patients with complex, chronic diseases.  Johnson et al’s, discovery of a small molecule, KGN, with further research in animal and human population, could lead to the development of an effective stem cell based treatment of Osteoarthritis. A possibility of such a drug can be seen as a lifestyle changing drug in patients who have very limited options of treatments today.

Sources:

Johnson et al article:  http://www.ncbi.nlm.nih.gov/pubmed/22491093

Arthritis information: http://orthopedics.about.com/cs/arthritis/a/arthritis.htm, h

http://www.cirm.ca.gov/node/2082

Stem cells: http://www.stemcellresources.org/pdf/uw_rm.pdf

http://stemcells.nih.gov/staticresources/info/scireport/PDFs/Regenerative_Medicine_2006.pdf

Kafienah et al article: http://www.ncbi.nlm.nih.gov/pubmed/17195220

Previous post in awesome capital on the paper by Johnson et. al. http://www.awesomecapital.com/1/post/2012/04/novartis-anti-arthritis-compound-spurs-cartilage-growth-from-stem-cells.html

Information about cartilage repair : http://www.jointpain.md/Procedures/CartilageTransplant.aspx

Cartilage Supplement in iHealth directory:http://www.ihealthdirectory.com/cartilage-regeneration-supplements/

Information about modern cartilage repair treatments offered at Brigham and Women Hospital: http://www.brighamandwomens.org/Departments_and_Services/orthopedics/services/CartilageRepair/default.aspx

Read Full Post »

 

How Genome Sequencing is Revolutionizing Clinical Diagnostics, from the ISMB Conference

Reporter: Aviva Lev-Ari, PhD, RN

 

08WednesdayAug 2012

Written by Filipe J. Ribeiro in Events

Filipe Ribeiro New York Genome CenterFilipe J. Ribeiro is a Bioinformatics Scientist at the New York Genome Center.

Recently, I attended the 20th Annual Conference of Intelligent Systems for Molecular Biology (July 15-17, 2012), organized by the International Society for Computational Biology. The conference focuses on the application of computer science, statistical, and mathematical methods to biological systems. I also attended the High Throughput Sequencing Methods and Applications (HiTSeq) satellite meeting (July 13-14, 2012). There, the speakers addressed the opportunities and challenges presented by the availability of the increasingly large genomic datasets from next-generation sequencing.

Many topics were discussed during the two days of HiTSeq, such as new data-analysis methods for RNA sequencing data, methods for improving de novoassemblies, and sequencing-data compression. What impressed me the most were the keynote addresses given by Dr. Stanley Nelson, from the Jonnson Comprehensive Cancer Center at UCLA, and Dr. Gohlson Lyon, from Cold Spring Harbor Laboratory. Both speakers focused on how whole-exome andwhole-genome sequencing are on the verge of revolutionizing clinical diagnosis of genetic disorders and what challenges need to be addressed before sequencing penetrates the clinic.

Dr. Nelson’s talk centered on the use of exome sequencing in the clinical diagnosis of genetic conditions. He presented a few case studies of young children with various rare developmental delays. Rare conditions can be hard to diagnose, and often times numerous tests need to be performed before a conclusion is reached, if a conclusion is reached at all. Also, some conditions are caused by a variety of different mutations to a single gene. These are harder to detect with conventional targeted genetic testing, which relies on known mutations. With exome sequencing a single test is performed; that one test identifies all coding mutations, known and unknown, simple and complex. Even when there is no smoking gun in the large set of mutations typically found in any single individual, the genotype can be reanalyzed at a later point, in light of new research findings.

However, challenges in genomics-based diagnosis still remain. Dr Nelson reports that in roughly 50 percent of cases studied clinically at UCLA, a known causal mutation is found. In 25 percent of cases, a novel genetic mutation is identified that is potentially causal, and in the remaining 25 percent of cases no conclusion can be drawn. Because of the large number of novel mutations that are present in any single individual’s genome, establishing causality of novel variations is often very hard, and care must be taken when interpreting results in order to avoid false positives. To minimize the risk of misdiagnosis in a clinical setting, it is fundamental to have a board of scientists and clinicians to review the conclusions of sequencing tests to ensure their validity.

Another challenge is what to do with secondary or unrelated findings—for example when a patient comes in with a set of symptoms indicative of one condition, and the genetic test finds a different one that is unrelated and asymptomatic. Some conditions (like Huntington’s disease) have no cure, and the patient might not want to learn about any diagnoses that are not actionable. A great deal of care must be taken both before and after genetic testing takes place so that patients understand the risks and the meaning of results.

On a slightly different note, Dr. Lyon focused on the ethical difficulties of returning research-grade results on genetic disorders to study participants. As an example he presented the case of a family that carries a genetic mutation that is fatal in boys at a very early age. A mutation was identified and shown to be causal in a research setting. The ethical dilemma for the researcher is: if one of the women in the family is pregnant with a boy, should she be informed of her carrier status? Research standards are not at the same level as clinical ones, and research results can at times be wrong.

It is not an easy question. Dr. Lyon’s suggestion is that research-grade whole-genome and whole-exome sequencing of study participants should be conducted under the same CLIA-certified standards as clinical tests, with the goal of returning research results to the study participants. Again, counseling and education of study participants regarding the risks and benefits of genetic testing are critical.

One barrier to the adoption of sequencing in a clinical setting is the fact that insurance companies do not cover the costs of whole genome sequencing as they are not yet convinced of the benefits. But that attitude will hopefully change as sequencing costs keep decreasing, and success stories abound. Soon it will be clear that genome sequencing is cost effective in disease diagnosis, prevention, and treatment. Also, for the most part genome sequencing is done only once in a lifetime, and therefore it is not a repetitive cost. (Cancer is an exception; one might want to sequence the cancer cells to identify which specific mutations are driving the tumor and to what drugs the tumor might respond.)

In summary, both speakers painted a picture of how whole-genome and whole-exome sequencing is quickly proving itself as a revolutionary tool in the clinic. Clearly challenges remain: test interpretation must be done carefully, ideally by a board of both scientists and clinicians, and strict CLIA standards should be in place, even in a research setting. But it is certainly clear that next generation sequencing will play an increasingly significant role in the clinic, and, most importantly, in our health.

 

http://blog.nygenome.org/

 

Read Full Post »

Innovations in Israel – Nobel Prize in Chemistry 2004, 2011

Reporter: Aviva Lev-Ari, PhD, RN

 

Prof. Avram Hershko – Science as an Adventure –

Nobel Prize in Chemistry 2004

Prof. Avram Hershko shared the 2004 Nobel Prize in Chemistry with Aaron Ciechanover and Irwin Rose for “for the discovery of ubiquitin-mediated protein degradation.” He is a research professor in the Department of Biochemistry at the Technion’s Rappaport Faculty of Medicine in Haifa.

http://www.youtube.com/watch?v=lGJvsmG3mhw&list=PL8814C902ACB98559&feature=plcp

Prof. Aaron Ciechanover – Intracellular Proteolysis as a Future Drug Development Platform –

Nobel Prize in Chemistry 2004

Prof. Dan Shechtman  –  was awarded to Dan Shechtman “for the discovery of quasicrystals”.

 Nobel Prize in Chemistry 2011

On Dec. 10, 2011 as Prof. Dan Shechtman received his Nobel prize in chemistry, hundreds of Technion students gathered in the Zielony Student Union to watch the ceremony live in the Heller Cinema. A standing ovation was given to Prof. Shechtman when he received the prize.

http://www.youtube.com/watch?v=MGC1K255y0M&feature=relmfu

http://www.youtube.com/watch?v=EZRTzOMHQ4s&feature=relmfu

Daniel Shechtman is awarded the Nobel Prize for his discovery of quasicrystals. Discussed here by Professor Martyn Poliakoff and Sixty Symbols’ Professor Phil Moriarty.

http://www.youtube.com/watch?v=QiT00AUwQl8&feature=fvwrel

Technion and Albert Einstein

http://www.youtube.com/watch?v=gNZ6uNtSUHI&feature=relmfu

Technion Robots — Snake, Worm, Wall Crawling, Algorithms, Multi Agent

http://www.youtube.com/watch?v=8HHb3Z4n-4M&feature=relmfu

Prof. Judea Pearl and Ruth Pearl Interview Technion Harvey Prize

http://www.youtube.com/watch?v=32vGtL7T6Og&feature=context-chf&playnext=1&list=PLF3C1A9B99F462C37

http://www.youtube.com/technion

Technion-Cornell Innovation Institute – Craig Gotsman Interview

Interview with Prof. Craig Gotsman, Technion Computer Science professor and Founding Director of TCII-Technion-Cornell Innovation Institute. This institute is a joint venture of the Technion and Cornell University, and will be a key component of the new Cornell NYC Tech campus, a unique high-tech graduate school to be established in New York City. The goal of the entire NYC Tech campus, and the TCII within it, as conceived by Mayor Bloomberg, is to turn NYC into the high-tech capital of the world. This will be achieved by developing TCII into a fertile breeding ground for high-tech engineers. Google, New York will be the interim home of the Technion-Cornell Innovation Institute (TCII) and the CornellNYC Tech Campus. Google will initially provide 22,000 square feet, expandable to 58,000 square feet – free of charge – until the completion of the Roosevelt Island campus in 2017.

http://www.youtube.com/watch?v=-va_ncrYWes

Technion Cornell NYC Tech Campus Interior View

http://www.youtube.com/watch?v=HkN1aysdhdQ

Israel — One Hundred Years of Science and Technology

http://www.youtube.com/watch?v=GzilbrH3CcA&NR=1&feature=endscreen

Technion: The Start-Up Nation University

Saul Singer, co-author with Dan Senor of the best- selling book, “Start-Up Nation: The Story of Israel’s Economic Miracle” discusses the book and Technion’s critical contribution to Israel’s start-up scenehttp://www.startupnationbook.com/ . Featured in this film are Technion alumni, Shai Agassi founder and chief executive of Better Placehttp://www.betterplace.com/ and Uzia Galil, the founding father of Israeli high-tech http://www.uzia.com/management/ . Galil founded Elron Electronic Industries and Elbit computers.

ISRAEL START-UP NATION

http://www.youtube.com/watch?v=3JN1xwlKmoQ&feature=relmfuhttp://www.youtube.com/watch?v=-EQliG9Wsdo&feature=related

Israel: A Leader in Business Innovation

http://www.youtube.com/watch?v=KHLyANGmLjQ&feature=related

Israel in pictures

http://www.youtube.com/watch?v=T5gKq_p135Q&feature=related

Israel from the Air part 1

http://www.youtube.com/watch?v=3WFgeI3CXAU&feature=related

Israel from the Air part 2

http://www.youtube.com/watch?v=S08vOHhAWY8&feature=relmfu

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

 

Synthetic Biology

This collection aims to highlight PLOS ONE‘s role in the emerging interdisciplinary field of synthetic biology. The collection has its roots in PLOS ONE‘s very first issue, which included two publications from the field and since then, the number of synthetic biology articles published by the journal has grown steadily. As the field continues to develop, this collection will be updated to include new publications, thereby tracking the evolution of this dynamic research area.

Synthetic biology occurs at the intersection of a number of traditional disciplines, including biology, chemistry, and engineering. It aims to create biological systems that can be programmed to do useful things such as producing drugs and biofuel. The interdisciplinary nature of synthetic biology can make it difficult to publish in traditional journals. PLOS ONE‘s broad scope, however, allows for the publication of work crossing many traditional research boundaries, making it an ideal venue for many different types of synthetic biology publications. In addition, the journal’s focus on rigorous peer review without considering impact has made it possible to publish a body of articles that truly reflects the multifaceted nature of this research area.

One overarching theme of synthetic biology is standardization, which can only be achieved through concerted community effort. To this end, each article published in PLOS ONE can be the start of a lively conversation. The ability to comment on articles provides the community with a means to engage in a dialogue focused on specific articles, and the “Share this Article” feature allows readers to quickly send an article they find interesting to their entire networks, because all the content is openly accessible.

Articles in the Synthetic Biology Collection are presented in order of publication date and new articles will be added as they are published. PLOS ONE welcomes submissions in this field.

Collection Citation: Synthetic Biology (2012) PLOS Collections:http://www.ploscollections.org/syntheticbiology

Image Credit: Ivan Morozov (Virginia Bioinformatics Institute)

SOURCE

http://www.ploscollections.org/article/browseIssue.action?issue=info:doi/10.1371/issue.pcol.v02.i18

PLOS ONE Launches Synthetic Biology Collection

By Rachel Bernstein
Posted: August 15, 2012

Today PLOS ONE is happy to announce the launch of the Synthetic Biology Collection, including over 50 papers published in the last six years that illustrate the many facets of this dynamically evolving research area.

Synthetic biology is an innovative emerging field that exists at the intersection of many traditional disciplines, including biology, chemistry, and engineering, with aims to create biological systems that can be programmed to do useful things like produce drugs or biofuels, among other applications. Despite its potential, the heavily interdisciplinary nature of the research can make it difficult to publish in traditional discipline-specific journals.

However, PLOS ONE’s broad scope allows for the publication of work crossing many traditional research boundaries, making it an ideal venue for many different types of synthetic biology research. For example, the papers in the collection cover topics including DNA synthesis and assembly, standardized biological “parts” akin to interchangeable mechanical parts, protein engineering, and complex network and pathway analysis and modeling, as described in theCollection Overview written by collection editors Jean Peccoud of Virginia Tech and Mark Isalan of the Centre for Genomic Regulation.

The Collection has roots in PLOS ONE’s very first issue, which included two publications from the field. Since then, the number of synthetic biology articles published in the journal has grown steadily. The collection launched today highlights selected synthetic biology articles published in PLOS ONE since 2006, and it is intended to be a growing resource that will be updated regularly with new papers as the field continues to grow and develop.

Collection Citation: Synthetic Biology (2012) PLOS Collections:http://www.ploscollections.org/syntheticbiology

Image Credit: Ivan Morozov (Virginia Bioinformatics Institute)

SOURCE

http://blogs.plos.org/everyone/2012/08/15/plos-one-launches-synthetic-biology-collection/

The PLOS ONE Synthetic Biology Collection: Six Years and Counting

Jean Peccoud, Mark Isalan

PLoS ONE:
Published 15 Aug 2012 | info:doi/10.1371/journal.pone.0043231

The PLOS ONE Synthetic Biology Collection: Six Years and Counting 

Jean Peccoud1,2*, Mark Isalan3

1 Virginia Bioinformatics Institute, Virginia Tech, Blacksburg, Virginia, United States of America, 2 Center for Systems Biology of Engineered Tissues, Institute for Critical Technologies and Applied Science, Virginia Tech, Blacksburg, Virginia, United States of America, 3 EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation (CRG) and UPF, Barcelona, Spain

Abstract 

Since it was launched in 2006, PLOS ONE has published over fifty articles illustrating the many facets of the emerging field of synthetic biology. This article reviews these publications by organizing them into broad categories focused on DNA synthesis and assembly techniques, the development of libraries of biological parts, the use of synthetic biology in protein engineering applications, and the engineering of gene regulatory networks and metabolic pathways. Finally, we review articles that describe enabling technologies such as software and modeling, along with new instrumentation. In order to increase the visibility of this body of work, the papers have been assembled into the PLOS ONE Synthetic Biology Collection (www.ploscollections.org/synbio). Many of the innovative features of the PLOS ONE web site will help make this collection a resource that will support a lively dialogue between readers and authors of PLOS ONE synthetic biology papers. The content of the collection will be updated periodically by including relevant articles as they are published by the journal. Thus, we hope that this collection will continue to meet the publishing needs of the synthetic biology community.

Citation: Peccoud J, Isalan M (2012) The PLOS ONE Synthetic Biology Collection: Six Years and Counting. PLoS ONE 7(8): e43231. doi:10.1371/journal.pone.0043231

Editor: Wei Ning Chen, Nanyang Technological University, Singapore

 

Received: May 23, 2012; Accepted: July 16, 2012; Published: August 15, 2012

Copyright: © 2012 Peccoud, Isalan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: JP is supported by National Science Foundation Awards 0850100 and 0963988 and by grants R01-GM078989 and R01-GM095955 from the National Institutes of Health. MI is funded by FP7 ERC 201249 ZINC-HUBS, Ministerio de Ciencia e Innovacion grant MICINN BFU2010-17953 and the MEC-EMBL agreement. The funders had no role in the preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: peccoud@vt.edu

Introduction

Synthetic biology is an emerging transdisciplinary field at the intersection between many engineering and scientific disciplines such as biology, chemical engineering, chemistry, electrical engineering, or computer science. The scientific milestone that inspired the development of synthetic biology is often regarded as the description of two artificial gene networks in the same issue of Nature in 2000 [1][2]. However, the year 2004 marks the emergence of synthetic biology as a scientific community. This is the year of the first synthetic biology conference, the first iGEM competition –where students compete to build biological systems (http://igem.org/) ― and the creation of the synthetic biology page on Wikipedia. Two years later, the first issue of PLOS ONE included two synthetic biology articles [3][4], marking the beginning of a trend. Since then, PLOS ONE has published a large number of articles covering all aspects of the field. Synthetic biologists resolutely push the limits of their specialties in ways that few established journals have been able to appreciate. Since the result is often more “how to build something that works” rather than primary biological insight, the papers can be hard to place in classical journals. Many synthetic biology authors have benefited from the innovative PLOS ONE editorial policy to publish scientifically sound research, irrespective of its anticipated significance.

The purpose of this article is to introduce the PLOS ONE Synthetic Biology Collection (www.ploscollections.org/synbio/). The collection highlights selected synthetic biology articles published in PLOS ONE since 2006, putting them together in one place for easy perusal. The website is intended to be a growing resource that will be updated regularly.

We review the collection here by organizing it into some broad categories: DNA synthesis and assembly, Biological parts, Protein engineering, Networks and pathways, Synthetic life, Software and modeling, and Instruments. The classification is our own; since many synthetic biology papers cited in this review span more than one category, it was sometimes difficult to assign them to one category rather than another. Nonetheless, this structure should aid in navigating the 50+ papers currently included in the collection.

Summary of Papers Included in the Collection 

DNA Synthesis and Assembly

Synthetic biology projects often begin with the assembly of complicated, multi-component gene constructs. Therefore, both DNA assembly and cloning technologies are critical enablers of synthetic biology. Not surprisingly, many recent PLOS ONE papers propose methods to improve the efficiency of the fabrication step of synthetic biology projects. For example, Golden Gate Cloning [5] is a one-step DNA assembly protocol that can join at least nine distinct DNA fragments into one plasmid vector. The technique employs type IIs restriction enzymes that cut DNA at some distance from their cognate DNA-binding site, thus allowing flexibility and uniqueness in the compatible sticky ends that are generated. A related technique is GoldenBraid Assembly [6], that also uses type IIs restriction enzymes, but applies them iteratively to standardized DNA parts (see the ‘Biological parts’ section below). This allows the indefinite growth of reusable gene modules. Similarly, type IIs restriction enzymes have been used to make a hierarchical modular cloning system aimed at making eukaryotic multigene constructs [7].

‘One-pot’ assembly and cloning systems are being developed by many groups, and the ideal systems use as few standardized components as possible. Circular polymerase extension cloning (CPEC) fits into this category, using a single polymerase to assemble and clone multiple inserts with any vector, in a one-step in vitro reaction [8]. Alternatively, successive hybridization assembling (SHA) also employs a single reaction in vitro [9].

As well as cloning one desired multi-component construct, many projects require degenerate cloning or mutagenesis to make combinatorial libraries of gene variants. The OmniChange technique, which simultaneously saturates five independent codons, has therefore been developed to generate full-length gene libraries with 5 degenerate NNK-codons while avoiding PCR-amplification [10]. Large libraries of genetic sequences can be derived from oligonucleotides synthetized in a microarray, and later pooled in libraries from which more complex sequences can be derived [11]. By combining linear DNA amplification and PCR, DNA libraries with hundreds to thousands of members can be synthesized.

PCR methods themselves can have certain limitations, such as difficulties in amplifying GC-rich DNA targets. One study optimized polymerase chain assembly (PCA) and ligase chain reaction (LCR) methods for the construction of two GC-rich gene fragments implicated in tumorigenesis, IGF2R and BRAF [12]. They found that LCR was superior and benefited from the addition of DMSO and betaine.

The many synthesis and assembly methods presented in the collection can be combined to streamline the fabrication steps of synthetic biology projects, by producing collections of standardized biological parts. Standard parts are themselves a distinctive feature of synthetic biology, as reviewed below.

Biological Parts

The Registry of Standard Biological Parts (www.partsregistry.org), based on the original vision of Tom Knight, is providing a rich collection of components for synthetic biology projects. Several articles in the PLOS ONE collection reflect the importance of this resource. For example, a global analysis of the Registry clone collection [13] helped identify certain discrepancies between the sequences recorded in the database and the physical sequences of some clones in the collection. These results prompted a change in the quality control of the submissions to the Registry that has greatly improved the overall quality of the collection. Moreover, the analysis of parts usage patterns led to organizational guidelines that may help design and manage these new types of scientific resources. As most parts in the registry are for prokaryotes, a eukaryotic collection of 52 parts was developed and is available for distribution[14]. This includes multiple cloning sites (MCS), common protein tags, protein reporters and selection markers, amongst others. Furthermore, most of the parts were designed in a format to allow fusions that maintain the reading frame.

As well as standardized coding regions, synthetic biology projects require well-characterized promoters to achieve desired expression strengths. In one study, a single yeast promoter was mutated to make a fine-graded output range promoter library [15]. Transcription Activator-Like Orthogonal Repressors were then developed synthetically to control expression of these promoters in an orthogonal manner. Such orthogonality or ‘non-cross-reactivity’ is necessary for engineering larger synthetic gene circuits that do not interfere with the physiology of the biological chassis in which they operate. Mammalian synthetic promoters have also been developed by analyzing motifs found in highly active human promoters. Thus, by modulating the amount of sequences rich in GC and CpGs, custom designed promoters were obtained [16].

Finally, entirely de novo parts that are found nowhere in nature have been engineered to slot into biological systems. Using E. coli lacking conditionally essential genes, entirely new functional proteins were obtained from scaffolds of randomized 4-helix bundles, rescuing stalled growth [17]. Similarly, a synthetic ATP-binding protein, evolved entirely from non-natural sequences, was expressed in E. coli, altering the levels of intracellular ATP [18]. Protein engineering approaches are thus a potential source of many new parts, as well as forming a branch of synthetic biology in their own right.

Protein Engineering

Protein engineering can take many forms, from directed evolution methods to protein design. The PLOS ONE Synthetic Biology Collection includes a wide range of studies in this broad field.

Phage display is one of the classic tools of protein engineering, allowing combinatorial libraries of randomized proteins to be selected from the surface of bacteriophages. Phage display was used to generate a new class of binding proteins targeted to the pointed-end of actin [19]. These proteins, called synthetic antigen binders (sABs), were based on an antibody-like scaffold where sequence diversity is introduced into the binding loops using a new “reduced genetic code” phage display library.

An example of targeted protein design was the design of a dual reporter, Gemini [20]. Here, β-galactosidase (β-gal) α-fragment was fused to GFP, resulting in increased β-gal activity and some decrease in GFP sensitivity. GFP was also modified in a study where the ten proline residues of enhanced green fluorescent protein (EGFP) were replaced by (4R)- and (4S)-fluoroprolines (FPro) [21]. In this way, protein folding and stability could be tuned.

A promising advance in the field of engineering custom sequence-specific DNA-binding proteins is the use of Transcription Activator-Like (TAL) proteins. Modular TAL units specify A, C, G or T and can be concatenated to make long designer DNA-binding domains. Thus, Golden TAL Technology [22] has adapted Golden Gate Cloning [5] for engineering new TAL proteins. These were shown to function in human and plant cells and to target activation of both exogenous and endogenous genes, after fusion with a VP16 activation domain.

As well as single proteins, entire pathways can nowadays be engineered. Computational redesign was used to create new periplasmic binding proteins in plants, to act as biosensors in combination with a histidine kinase signaling cascade [23]. This resulted in transcription factor activation and ‘de-greening’ of plants in response to small-molecule stimuli. As can be seen from this example and the ones below, the move from single protein engineering to network engineering is one of the main driving forces in synthetic biology.

Networks and Pathways

One of the first, and now most-cited, synthetic biology papers in PLOS ONE was the study on fitness-induced attractor selection [3]. Here, a synthetic mutual inhibition gene network was built in E. coli, with two states, green (GFP) and red (RFP), that were mutually exclusive. By attaching a fitness pressure to one of the states (i.e. a gene required for growth in the absence of glutamine), the authors demonstrated that the cells switched stochastically into the fittest state, restoring growth. In other words, by changing to a glutamine-free medium, the red cells switched to green, even in the absence of formal signaling machinery. This work has important messages for potential new mechanisms in gene regulation, where underlying fitness pressures can ultimately determine how much a gene is expressed, simply according to need.

Other small bacterial networks have been built to include a heritable sequential memory switch, using the fim and hin inversion recombination systems [24], and an E. coli strain for use as a ‘chemical recording device’ [25]. In the latter, the authors created a synthetic chemically sensitive genetic toggle switch to activate appropriate fluorescent protein indicators (GFP, RFP) and along with a cell division inhibitor (minC). Moving to yeast, one example of network engineering was the reconstruction of a human p53-Mdm2 negative feedback module in S. cerevisiae [26]. In this example, many aspects of p53 regulation in mammals were maintained, such as Mdm2-dependent targeting of p53 for degradation, sumoylation at lysine 386 and further regulation of this process by p14ARF. In mammalian systems, a synthetic tetracycline regulator positive feedback loop was stably integrated and yielded a bimodal expression response because such cells can only be “OFF” or “ON” [27].

One unusual work in synthetic biology aimed to rewire and control cell shape in yeast, by changing the inputs into the α-factor pathway [28]. This pathway can give rise to multiple mating projections, upon prolonged activation. The authors tested genetic manipulations that ultimately gave rise to single or multiple projections, in the absence of the natural input, α-factor.

A group of papers in the collection explore ‘synthetic ecology’, where consortia of different cells interact to give patterns at a population level. For example, by engineering two strains of E. coli, one study was able to achieve synthetic biofilms with spatial self-organization [29]. The consortia achieved defined layered structures and had unexpected growth advantages. A second paper describes a systems composed of two quorum-sensing signal transduction circuits that allowed the authors to build a synthetic ecosystem where the population dynamics could be tuned by varying the environmental signals [30]. Third, quorum components were also used in a study which generated robust but unexpected oscillations in E. coli by building synthetic suicide circuits [31]. In fact, the quorum components proved to be unnecessary to achieve oscillations: there was a density-dependent plasmid amplification that gave rise to population-level negative feedback, ultimately resulting in the cycles. As in other areas of synthetic biology, the process of building systems often leads to surprises which can result in useful new engineering tools, or to a better understanding of the underlying biological processes [32].

Pathway engineering for the production of useful chemical or product synthesis is a major field within synthetic biology. For example, an engineered yeast that efficiently secretes penicillin was built by transplanting synthesis pathway components into a host that is more suited for pharmaceutical production [33]. Artemisinin derivatives are key components of malaria therapies and their synthesis is a high-profile goal of synthetic biology because extraction from slow-growing plants currently limits supply. Consequently, one study achieved high-level production of an artemisinin precursor in E. coli[34]. Another striking synthesis paper demonstrates a synthetic enzymatic pathway consisting of 13 enzymes for high-yield hydrogen production from starch and water [35]. Building such large systems is extremely challenging; as a result, these articles have received a lot of attention.

Synthetic Life

Synthetic life is among the most controversial of synthetic biology aims, and has received a lot of attention, even in the mainstream press. Public concerns of possible biological threats resulting from the misuse of these technologies prompted the development of new biosecurity policies [36].

One branch of this field is the de novo chemical synthesis and assembly of whole plasmids, viruses and genomes which are then transplanted into host cells. The pX1.0 plasmid is an example of a fully chemically-synthesized plasmid designed by calculating consensus sequences from 8 plasmids [37], while removing genes involved in antibiotic resistance and virulence. The plasmid not only replicated inE. coli, but could also self-transfer by conjugation into two other enterobacter species. A chemical synthesis approach was also used to construct whole genomes of bacteriophage G4 (around 10 kilobases in length), resulting in infectious viruses that could pass from one strain of E. coli to another[38].

One group has the ambitious long-term aim of building a synthetic chloroplast, and has begun by transplanting photosynthetic bacteria into eukaryotic cells to see whether they can achieve synthetic symbiosis [39]. Remarkably, the authors showed that some cyanobacteria were relatively harmless in zebrafish embryos, compared to E. coli. Furthermore, by engineering invasins into the cyanobacteria, they were able to invade and divide inside mammalian macrophages. Synthetic biology is only limited by our imagination, and one can speculate that entire free-living synthetic lifeforms could find their place in the collection in the not-too-distant future.

Software and Modeling

As the number of biological parts for synthetic biology increases, databases and design methods must evolve. For example, to help researchers search and retrieve biological parts, the Knowledgebase of Standard Biological Parts (SBPkb) is a Semantic Web resource for synthetic biology [40].

The collection also includes two articles presenting Computer Assisted Design software tools. Eugene is a human readable language to specify synthetic biological designs based on biological parts. It also provides a very expressive constraint system to drive the automatic creation of composite parts or devices from a collection of individual parts [41]. Alternatively, the Proto platform also provides a high-level biologically-oriented programming language [42]. Specifications are compiled from regulatory motifs, optimized, then converted into computational simulations for numerical verification.

Ultimately the design tools are only as good as the underlying mathematical models they rely on to make predictions of design behaviors. The collection includes a number of articles applying mathematical modeling approaches rooted in various engineering specialties to the design of synthetic genetic constructs.

Modeling gene networks is at the interface of systems and synthetic biology, and many PLOS ONE modeling papers aim to guide bioengineering projects. A recent example of adapting modeling for re-engineering properties into a system used a standardized synthetic yeast network from the In-vivo Reverse-engineering and Modeling Assessment (IRMA) [43]. Reverse engineering itself was used in a study which ultimately provided guidelines for chemotaxis pathway redesign [44]. Statecharts are used to describe dynamical systems, but have not been applied to gene networks. By doing so explicitly, one study was able to model network motifs and combine them in a complicated interlocked feed-forward loop network [45].

Two-component systems are common regulatory motifs in bacteria, and comprise a kinase that senses environmental signals together with a regulator that mediates the cell response. A recent study asked the question, “what happens if you add a third component that interacts with either of the other two?”[46]. Estimating the parameter space associated with a particular function is very valuable for guiding synthetic engineering approaches, as is determining whether a function is theoretically possible at all. For example, using a geometric argument, it was shown that, surprisingly, even monomer regulators can achieve bistability. This demonstrates the possibility of switch-like behavior in feedback autoloops without resorting to multimer regulators [47].

thumbnailFigure 1. Historical distribution of synthetic biology articles published by PLOS ONE.

This figure reports the number of articles in the collection published between 2006 and 2011. It shows a rapid growth of synthetic biology that reflects the growth of the journal and the increased familiarity of synthetic biologists with PLOS ONE.

doi:10.1371/journal.pone.0043231.g001

By combining experiments and computation, one study was able to derive design algorithms for altering synonymous codons in proteins, resulting in drastic expression differences of the same protein sequence[48]. For example, with DNA polymerase and single chain antibodies, expression could be predictably tuned to obtain concentrations ranging from undetectable to 30% of cellular protein. Importantly, using partial least squares regression, the authors noticed that favorable codons were predominantly those read by tRNAs that are most highly charged during amino acid starvation, not codons that are most abundant in highly expressed E. coli proteins. This is an important discovery for building genetic constructs that express appropriately inside the target cells.

Computation is a key function of biological networks and several studies in the collection present schemes to achieve this. The first is implemented at the level of chemical reactions and describes functions such as an inverter, an incrementer, a decrementer, a copier, a comparator, a multiplier, an exponentiator, a raise-to-a-power operation, and a logarithm in base two [49]. A key simplification is that the scheme uses only two reaction rates (“fast” and “slow”). A second study models a synthetic gene network to perform frequency multiplication [50]. Both of these studies assume deterministic relationships between input and outputs. Recently, the deterministic assumption has been challenged by experimental and theoretical works analyzing the importance of noise in the dynamics of gene networks [51]. This trend is illustrated in the collection by an article demonstrating that reliable timing of decision-making processes (choosing between multistable states) can be accomplished for large enough population sizes, as long as cells are globally coupled by chemical means [52]. Modeling can often reveal subtle non-intuitive designs, and, as a means of guiding synthetic biology, is likely to become an even larger field in the future.

thumbnailFigure 2. Relationships between article-level metrics.

For articles published between 2006 and 2009, there is a positive correlation between the number of times an article is cited in the scientific literature and the number of times it is viewed (A). For articles published between 2010 and 2012, there is a positive relationship between the number of views and the number of citations in the Mendeley social network (B). Metrics, such as number of views and citations in social media, give readers and authors an estimate of the scientific impact of individual articles well before they receive citations in scientific literature.

doi:10.1371/journal.pone.0043231.g002

Instruments

Nowadays, new technology and machinery is an important driving force for both primary biological discovery and for synthetic biology. A neat example is provided by the use of inkjet printer technology to provide low-cost high-resolution tools; a bacterial piezoelectric inkjet printer was designed to print out different strains of bacteria or chemicals in small droplets onto a flat surface at high resolution [53]. Another group used an inkjet for continuous dosing of diffusible regulators to a gel culture of E. coli, allowing 2D spatiotemporal regulation [54]. Precise spatiotemporal control of cells can also be achieved with microfluidics, and a recent report grew dividing yeast cells in a remarkable planar array [55]. Transient pulses of gene expression could be triggered by briefly inducing the GAL1 or MET3 promoters, resulting in coherent induction of cell division across the cell cluster. Other novel culture systems presented in the collection include the development of a 3-D cell culture system using a designer peptide nanofiber scaffold that self-assembled [4]. The peptide could be linked to functional motifs for cell adhesion, differentiation, and bone marrow homing for use with mouse adult neural stem cells.

The Synthetic Biology Collection: A Dynamic Community Resource Top

It is remarkable that the collection includes several articles originating from engineers and computer scientists who traditionally publish their work in conference proceedings rather than the journals available to life-scientists. PLOS ONE’s indifference to subject matter made it possible to publish an unprecedented body of articles that reflects the multi-faceted nature of synthetic biology. No less remarkable is the observation that PLOS ONE published several articles originating from iGEM projects[13][41][56].

Since 2006, the number of synthetic biology articles published by the journal has been growing steadily (Figure 1). This evolution is consistent with the social trends in synthetic biology that have been mapped in an interesting bibliometric analysis included in the collection [57]. This is an indication that the synthetic biology community is becoming more aware of the services provided by the journal. Looking forward, the collection will make it easier to identify synthetic biology articles among the quickly growing volume of articles published by the journal each day. The content of the collection will be updated periodically as new synthetic biology articles are published by the journal.

Although Journal Impact Factors are a widely-discredited form of evaluating the quality of individual papers, all too often they are still used. Thus, it is imperative to find a better alternative. One of the most exciting features of the PLOS ONE web site is the Metrics tab, displaying article-based metrics that can be used to assess the impact of individual articles. These metrics naturally include traditional indicators, such as the number of citations. The two articles of the collection published in 2006 have been cited 70 and 84 times so far. Almost all the articles published in 2007 and 2008 have received more than 10 citations. The lag between the publication of an article and its citation by others is well known. Fortunately, the Metrics tab also includes more innovative indicators that give the authors and readers alike a real-time estimate of the ‘impact’ of an article. The number of times an article is viewed is an important indicator. Since PLOS ONE is an online journal, all readers view articles online in one way or another. As a result, we hypothesized that the number of times an article was viewed should be a good predictor of the number of citations it will receive. Using data reported in Table S1, we analyzed the relationship between views and citation numbers for articles included in the collection that were published between 2006 and 2009. Figure 2 shows that there is a positive correlation between the two metrics. That relationship does not hold when including more recent articles because of a difference in timing between viewing and citing activities. Articles typically receive a substantial number of views in the first few months after publication, but it takes a few years before they are cited. The 20 articles of the collection published in 2011 have recorded a lot of views, but have not had the time to be cited in the literature yet.

A non-conventional form of citations displayed in the Metrics tab is the number of times an article is bookmarked in social media. We have reported the Mendeley (www.mendeley.com) data in Table S1.Figure 2 shows that there is a positive relationship between the number of views and the number of times articles are bookmarked in this network, at least for the most recent articles of the collection. Older articles are under-represented in Mendeley because this network was not available at the time these articles were published. It will be interesting to see if citations of the collection articles in social media will be a better predictor of citations in the scientific literature than the number of views.

One overarching theme of synthetic biology is standardization [58][59], which can only be achieved through concerted efforts by members of the community. The field has therefore been deeply influenced by the development of resources such as the Registry of Standard Biological Parts (www.partsregistry.org ). More recently, the development of SBOL, the Open Language for Synthetic Biology (www.sbolstandard.org) illustrates the need to agree on data formats suitable to the development of software tool chains necessary to support experimental efforts. Each article published in PLOS ONE can be the start of a lively conversation. The journal web site provides authors and readers alike with a detailed vision of community connections. The “Share this article” feature allows readers to quickly send an article they find interesting to their networks. The comments tab of the articles provides the community with means to engage in a dialogue focused on specific articles [5][35][48][55]. This feature can also be used by authors to provide updated information about the work presented in the article [13].

When working at its best, science should be an active conversation that keeps refining ideas. We believe that PLOS ONE provides the ideal venue to achieve this, and we hope that the collection will inspire further progress in synthetic biology. Ultimately, we hope that having a clear repository in PLOS ONE should further increase its attractiveness as a home for publishing synthetic biology.

Table S1.

Article-level statistics for the Synthetic Biology Collection.

(XLSX)

Author Contributions

Wrote the paper: JP MI.

References Top

  1. Elowitz MB, Leibler S (2000) A synthetic oscillatory network of transcriptional regulators. Nature 403: 335–338. FIND THIS ARTICLE ONLINE
  2. Gardner TS, Cantor CR, Collins JJ (2000) Construction of a genetic toggle switch in Escherichia coli. Nature 403: 339–342. FIND THIS ARTICLE ONLINE
  3. Kashiwagi A, Urabe I, Kaneko K, Yomo T (2006) Adaptive Response of a Gene Network to Environmental Changes by Fitness-Induced Attractor Selection. PLoS ONE 1: e49. FIND THIS ARTICLE ONLINE
  4. Gelain F, Bottai D, Vescovi A, Zhang S (2006) Designer Self-Assembling Peptide Nanofiber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional Cultures. PLoS ONE 1: e119. FIND THIS ARTICLE ONLINE
  5. Engler C, Gruetzner R, Kandzia R, Marillonnet S (2009) Golden gate shuffling: a one-pot DNA shuffling method based on type IIs restriction enzymes. PLoS One 4: e5553. FIND THIS ARTICLE ONLINE
  6. Sarrion-Perdigones A, Falconi E, Zandalinas S, Juárez P, Fernández-del-Carmen A, et al. (2011) GoldenBraid: An Iterative Cloning System for Standardized Assembly of Reusable Genetic Modules. PLoS ONE 6: e21622. FIND THIS ARTICLE ONLINE
  7. Weber E, Engler C, Gruetzner R, Werner S, Marillonnet S (2011) A Modular Cloning System for Standardized Assembly of Multigene Constructs. PLoS ONE 6: e16765. FIND THIS ARTICLE ONLINE
  8. Quan J, Tian J (2009) Circular Polymerase Extension Cloning of Complex Gene Libraries and Pathways. PLoS ONE 4: e6441. FIND THIS ARTICLE ONLINE
  9. Jiang X, Yang J, Zhang H, Zou H, Wang C, et al. (2012) In Vitro Assembly of Multiple DNA Fragments Using Successive Hybridization. PLoS ONE 7: e30267. FIND THIS ARTICLE ONLINE
  10. Dennig A, Shivange A, Marienhagen J, Schwaneberg U (2011) OmniChange: The Sequence Independent Method for Simultaneous Site-Saturation of Five Codons. PLoS ONE 6: e26222.FIND THIS ARTICLE ONLINE
  11. Svensen N, Díaz-Mochón JJ, Bradley M (2011) Microarray generation of thousand-member oligonucleotide libraries. PLoS ONE 6: e24906. FIND THIS ARTICLE ONLINE
  12. Jensen M, Fukushima M, Davis R (2010) DMSO and Betaine Greatly Improve Amplification of GC-Rich Constructs in De Novo Synthesis. PLoS ONE 5: e11024. FIND THIS ARTICLE ONLINE
  13. Peccoud J, Blauvelt MF, Cai Y, Cooper KL, Crasta O, et al. (2008) Targeted Development of Registries of Biological Parts. PLoS ONE 3: e2671. FIND THIS ARTICLE ONLINE
  14. Constante M, Grünberg R, Isalan M (2011) A Biobrick Library for Cloning Custom Eukaryotic Plasmids. PLoS ONE 6: e23685. FIND THIS ARTICLE ONLINE
  15. Blount BA, Weenink T, Vasylechko S, Ellis T (2012) Rational Diversification of a Promoter Providing Fine-Tuned Expression and Orthogonal Regulation for Synthetic Biology. PLoS ONE 7: e33279.FIND THIS ARTICLE ONLINE
  16. Grabherr M, Pontiller J, Mauceli E, Ernst W, Baumann M, et al. (2011) Exploiting Nucleotide Composition to Engineer Promoters. PLoS ONE 6: e20136. FIND THIS ARTICLE ONLINE
  17. Fisher M, McKinley K, Bradley L, Viola S, Hecht M (2011) De Novo Designed Proteins from a Library of Artificial Sequences Function in Escherichia Coli and Enable Cell Growth. PLoS ONE 6: e15364.FIND THIS ARTICLE ONLINE
  18. Stomel J, Wilson J, León M, Stafford P, Chaput J (2009) A Man-Made ATP-Binding Protein Evolved Independent of Nature Causes Abnormal Growth in Bacterial Cells. PLoS ONE 4: e7385. FIND THIS ARTICLE ONLINE
  19. Brawley C, Uysal S, Kossiakoff A, Rock R (2010) Characterization of Engineered Actin Binding Proteins That Control Filament Assembly and Structure. PLoS ONE 5: e13960. FIND THIS ARTICLE ONLINE
  20. Martin L, Che A, Endy D (2009) Gemini, a bifunctional enzymatic and fluorescent reporter of gene expression. PLoS One 4: e7569. FIND THIS ARTICLE ONLINE
  21. Steiner T, Hess P, Bae JH, Wiltschi B, Moroder L, et al. (2008) Synthetic Biology of Proteins: Tuning GFPs Folding and Stability with Fluoroproline. PLoS ONE 3: e1680. FIND THIS ARTICLE ONLINE
  22. Weber E, Gruetzner R, Werner S, Engler C, Marillonnet S (2011) Assembly of Designer TAL Effectors by Golden Gate Cloning. PLoS ONE 6: e19722. FIND THIS ARTICLE ONLINE
  23. Antunes M, Morey K, Smith J, Albrecht K, Bowen T, et al. (2011) Programmable Ligand Detection System in Plants through a Synthetic Signal Transduction Pathway. PLoS ONE 6: e16292. FIND THIS ARTICLE ONLINE
  24. Ham T, Lee S, Keasling J, Arkin A (2008) Design and Construction of a Double Inversion Recombination Switch for Heritable Sequential Genetic Memory. PLoS ONE 3: e2815. FIND THIS ARTICLE ONLINE
  25. Bhomkar P, Materi W, Wishart D (2011) The Bacterial Nanorecorder: Engineering E. coli to Function as a Chemical Recording Device. PLoS ONE 6: e27559. FIND THIS ARTICLE ONLINE
  26. Di Ventura B, Funaya C, Antony C, Knop M, Serrano L (2008) Reconstitution of Mdm2-Dependent Post-Translational Modifications of p53 in Yeast. PLoS ONE 3: e1507. FIND THIS ARTICLE ONLINE
  27. May T, Eccleston L, Herrmann S, Hauser H, Goncalves J, et al. (2008) Bimodal and Hysteretic Expression in Mammalian Cells from a Synthetic Gene Circuit. PLoS ONE 3: e2372. FIND THIS ARTICLE ONLINE
  28. Tanaka H, Yi T-M (2009) Synthetic Morphology Using Alternative Inputs. PLoS ONE 4: e6946.FIND THIS ARTICLE ONLINE
  29. Brenner K, Arnold F (2011) Self-Organization, Layered Structure, and Aggregation Enhance Persistence of a Synthetic Biofilm Consortium. PLoS ONE 6: e16791. FIND THIS ARTICLE ONLINE
  30. Hu B, Du J, Zou R-y, Yuan Y-j (2010) An Environment-Sensitive Synthetic Microbial Ecosystem. PLoS ONE 5: e10619. FIND THIS ARTICLE ONLINE
  31. Marguet P, Tanouchi Y, Spitz E, Smith C, You L (2010) Oscillations by Minimal Bacterial Suicide Circuits Reveal Hidden Facets of Host-Circuit Physiology. PLoS ONE 5: e11909. FIND THIS ARTICLE ONLINE
  32. Elowitz M, Lim WA (2010) Build life to understand it. Nature 468: 889–890. FIND THIS ARTICLE ONLINE
  33. Gidijala L, Kiel J, Douma R, Seifar R, van Gulik W, et al. (2009) An Engineered Yeast Efficiently Secreting Penicillin. PLoS ONE 4: e8317. FIND THIS ARTICLE ONLINE
  34. Tsuruta H, Paddon C, Eng D, Lenihan J, Horning T, et al. (2009) High-Level Production of Amorpha-4,11-Diene, a Precursor of the Antimalarial Agent Artemisinin, in Escherichia coli. PLoS ONE 4: e4489. FIND THIS ARTICLE ONLINE
  35. Zhang P, Evans B, Mielenz J, Hopkins R, Adams M (2007) High-Yield Hydrogen Production from Starch and Water by a Synthetic Enzymatic Pathway. PLoS ONE 2: e456. FIND THIS ARTICLE ONLINE
  36. Adam L, Kozar M, Letort G, Mirat O, Srivastava A, et al. (2011) Strengths and limitations of the federal guidance on synthetic DNA. Nat Biotechnol 29: 208–210. FIND THIS ARTICLE ONLINE
  37. Hansen L, Bentzon-Tilia M, Bentzon-Tilia S, Norman A, Rafty L, et al. (2011) Design and Synthesis of a Quintessential Self-Transmissible IncX1 Plasmid, pX1.0. PLoS ONE 6: e19912. FIND THIS ARTICLE ONLINE
  38. Yang R, Han Y, Ye Y, Liu Y, Jiang Z, et al. (2011) Chemical Synthesis of Bacteriophage G4. PLoS ONE 6: e27062. FIND THIS ARTICLE ONLINE
  39. Agapakis C, Niederholtmeyer H, Noche R, Lieberman T, Megason S, et al. (2011) Towards a Synthetic Chloroplast. PLoS ONE 6: e18877. FIND THIS ARTICLE ONLINE
  40. Galdzicki M, Rodriguez C, Chandran D, Sauro H, Gennari J (2011) Standard Biological Parts Knowledgebase. PLoS ONE 6: e17005. FIND THIS ARTICLE ONLINE
  41. Bilitchenko L, Liu A, Cheung S, Weeding E, Xia B, et al. (2011) Eugene – A Domain Specific Language for Specifying and Constraining Synthetic Biological Parts, Devices, and Systems. PLoS ONE 6: e18882. FIND THIS ARTICLE ONLINE
  42. Beal J, Lu T, Weiss R (2011) Automatic Compilation from High-Level Biologically-Oriented Programming Language to Genetic Regulatory Networks. PLoS ONE 6: e22490. FIND THIS ARTICLE ONLINE
  43. Marucci L, Barton D, Cantone I, Ricci M, Cosma M, et al. (2009) How to Turn a Genetic Circuit into a Synthetic Tunable Oscillator, or a Bistable Switch. PLoS ONE 4: e8083. FIND THIS ARTICLE ONLINE
  44. Luo J, Wang J, Ma T, Sun Z (2010) Reverse Engineering of Bacterial Chemotaxis Pathway via Frequency Domain Analysis. PLoS ONE 5: e9182. FIND THIS ARTICLE ONLINE
  45. Shin Y-J, Nourani M (2010) Statecharts for Gene Network Modeling. PLoS ONE 5: e9376. FIND THIS ARTICLE ONLINE
  46. Salvado B, Vilaprinyo E, Karathia H, Sorribas A, Alves R (2012) Two Component Systems: Physiological Effect of a Third Component. PLoS ONE 7: e31095. FIND THIS ARTICLE ONLINE
  47. Widder S, Macía J, Solé R (2009) Monomeric Bistability and the Role of Autoloops in Gene Regulation. PLoS ONE 4: e5399. FIND THIS ARTICLE ONLINE
  48. Welch M, Govindarajan S, Ness J, Villalobos A, Gurney A, et al. (2009) Design Parameters to Control Synthetic Gene Expression in Escherichia coli. PLoS ONE 4: e7002. FIND THIS ARTICLE ONLINE
  49. Senum P, Riedel M (2011) Rate-Independent Constructs for Chemical Computation. PLoS ONE 6: e21414. FIND THIS ARTICLE ONLINE
  50. Purcell O, di Bernardo M, Grierson C, Savery N (2011) A Multi-Functional Synthetic Gene Network: A Frequency Multiplier, Oscillator and Switch. PLoS ONE 6: e16140. FIND THIS ARTICLE ONLINE
  51. Balazsi G, van Oudenaarden A, Collins JJ (2011) Cellular decision making and biological noise: from microbes to mammals. Cell 144: 910–925. FIND THIS ARTICLE ONLINE
  52. Koseska A, Zaikin A, Kurths J, García-Ojalvo J (2009) Timing Cellular Decision Making Under Noise via Cell–Cell Communication. PLoS ONE 4: e4872. FIND THIS ARTICLE ONLINE
  53. Merrin J, Leibler S, Chuang JS (2007) Printing multistrain bacterial patterns with a piezoelectric inkjet printer. PLoS ONE 2: e663. FIND THIS ARTICLE ONLINE
  54. Cohen D, Morfino R, Maharbiz M (2009) A Modified Consumer Inkjet for Spatiotemporal Control of Gene Expression. PLoS ONE 4: e7086. FIND THIS ARTICLE ONLINE
  55. Charvin G, Cross FR, Siggia ED (2008) A microfluidic device for temporally controlled gene expression and long-term fluorescent imaging in unperturbed dividing yeast cells. PLoS One 3: e1468. FIND THIS ARTICLE ONLINE
  56. Hesselman MC, Odoni DI, Ryback BM, de Groot S, van Heck RG, et al. (2012) A multi-platform flow device for microbial (co-) cultivation and microscopic analysis. PLoS One 7: e36982. FIND THIS ARTICLE ONLINE
  57. Oldham P, Hall S, Burton G (2012) Synthetic biology: mapping the scientific landscape. PLoS One 7: e34368. FIND THIS ARTICLE ONLINE
  58. Endy D (2005) Foundations for engineering biology. Nature 438: 449–453. FIND THIS ARTICLE ONLINE
  59. Canton B, Labno A, Endy D (2008) Refinement and standardization of synthetic biological parts and devices. Nat Biotechnol 26: 787–793. FIND THIS ARTICLE ONLINE
SOURCE

Research Articles

A Multi-Platform Flow Device for Microbial (Co-) Cultivation and Microscopic Analysis

Matthijn C. Hesselman, Dorett I. Odoni, Brendan M. Ryback, Suzette de Groot, Ruben G. A. van Heck, Jaap Keijsers, Pim Kolkman, David Nieuwenhuijse, Youri M. van Nuland, Erik Sebus, Rob Spee, Hugo de Vries, Marten T. Wapenaar, Colin J. Ingham, Karin Schroën, Vítor A. P. Martins dos Santos, Sebastiaan K. Spaans, Floor Hugenholtz, Mark W. J. van Passel

PLoS ONE:
Published 14 May 2012 | info:doi/10.1371/journal.pone.0036982

Synthetic Biology: Mapping the Scientific Landscape

Paul Oldham, Stephen Hall, Geoff Burton

PLoS ONE:
Published 23 Apr 2012 | info:doi/10.1371/journal.pone.0034368

Rational Diversification of a Promoter Providing Fine-Tuned Expression and Orthogonal Regulation for Synthetic Biology

Benjamin A. Blount, Tim Weenink, Serge Vasylechko, Tom Ellis

PLoS ONE:
Published 19 Mar 2012 | info:doi/10.1371/journal.pone.0033279

Two Component Systems: Physiological Effect of a Third Component

Baldiri Salvado, Ester Vilaprinyo, Hiren Karathia, Albert Sorribas, Rui Alves

PLoS ONE:
Published 17 Feb 2012 | info:doi/10.1371/journal.pone.0031095

In Vitro Assembly of Multiple DNA Fragments Using Successive Hybridization

Xinglin Jiang, Jianming Yang, Haibo Zhang, Huibin Zou, Cong Wang, Mo Xian

PLoS ONE:
Published 26 Jan 2012 | info:doi/10.1371/journal.pone.0030267

The Bacterial Nanorecorder: Engineering E. coli to Function as a Chemical Recording Device

Prasanna Bhomkar, Wayne Materi, David S. Wishart

PLoS ONE:
Published 23 Nov 2011 | info:doi/10.1371/journal.pone.0027559

Chemical Synthesis of Bacteriophage G4

Ruilin Yang, Yonghua Han, Yiwang Ye, Yuchen Liu, Zhimao Jiang, Yaoting Gui, Zhiming Cai

PLoS ONE:
Published 16 Nov 2011 | info:doi/10.1371/journal.pone.0027062

OmniChange: The Sequence Independent Method for Simultaneous Site-Saturation of Five Codons

Alexander Dennig, Amol V. Shivange, Jan Marienhagen, Ulrich Schwaneberg

PLoS ONE:
Published 19 Oct 2011 | info:doi/10.1371/journal.pone.0026222

Microarray Generation of Thousand-Member Oligonucleotide Libraries

Nina Svensen, Juan José Díaz-Mochón, Mark Bradley

PLoS ONE:
Published 23 Sep 2011 | info:doi/10.1371/journal.pone.0024906

A Biobrick Library for Cloning Custom Eukaryotic Plasmids

Marco Constante, Raik Grünberg, Mark Isalan

PLoS ONE:
Published 25 Aug 2011 | info:doi/10.1371/journal.pone.0023685

Automatic Compilation from High-Level Biologically-Oriented Programming Language to Genetic Regulatory Networks

Jacob Beal, Ting Lu, Ron Weiss

PLoS ONE:
Published 05 Aug 2011 | info:doi/10.1371/journal.pone.0022490

GoldenBraid: An Iterative Cloning System for Standardized Assembly of Reusable Genetic Modules

Alejandro Sarrion-Perdigones, Erica Elvira Falconi, Sara I. Zandalinas, Paloma Juárez, Asun Fernández-del-Carmen, Antonio Granell, Diego Orzaez

PLoS ONE:
Published 07 Jul 2011 | info:doi/10.1371/journal.pone.0021622

Rate-Independent Constructs for Chemical Computation

Phillip Senum, Marc Riedel

PLoS ONE:
Published 30 Jun 2011 | info:doi/10.1371/journal.pone.0021414

Assembly of Designer TAL Effectors by Golden Gate Cloning

Ernst Weber, Ramona Gruetzner, Stefan Werner, Carola Engler, Sylvestre Marillonnet

PLoS ONE:
Published 19 May 2011 | info:doi/10.1371/journal.pone.0019722

Design and Synthesis of a Quintessential Self-Transmissible IncX1 Plasmid, pX1.0

Lars H. Hansen, Mikkel Bentzon-Tilia, Sara Bentzon-Tilia, Anders Norman, Louise Rafty, Søren J. Sørensen

PLoS ONE:
Published 18 May 2011 | info:doi/10.1371/journal.pone.0019912

Exploiting Nucleotide Composition to Engineer Promoters

Manfred G. Grabherr, Jens Pontiller, Evan Mauceli, Wolfgang Ernst, Martina Baumann, Tara Biagi, Ross Swofford, Pamela Russell, Michael C. Zody, Federica Di Palma, Kerstin Lindblad-Toh, Reingard M. Grabherr

PLoS ONE:
Published 18 May 2011 | info:doi/10.1371/journal.pone.0020136

Eugene – A Domain Specific Language for Specifying and Constraining Synthetic Biological Parts, Devices, and Systems

Lesia Bilitchenko, Adam Liu, Sherine Cheung, Emma Weeding, Bing Xia, Mariana Leguia, J. Christopher Anderson, Douglas Densmore

PLoS ONE:
Published 29 Apr 2011 | info:doi/10.1371/journal.pone.0018882

Towards a Synthetic Chloroplast

Christina M. Agapakis, Henrike Niederholtmeyer, Ramil R. Noche, Tami D. Lieberman, Sean G. Megason, Jeffrey C. Way, Pamela A. Silver

PLoS ONE:
Published 20 Apr 2011 | info:doi/10.1371/journal.pone.0018877

Standard Biological Parts Knowledgebase

Michal Galdzicki, Cesar Rodriguez, Deepak Chandran, Herbert M. Sauro, John H. Gennari

PLoS ONE:
Published 24 Feb 2011 | info:doi/10.1371/journal.pone.0017005

A Modular Cloning System for Standardized Assembly of Multigene Constructs

Ernst Weber, Carola Engler, Ramona Gruetzner, Stefan Werner, Sylvestre Marillonnet

PLoS ONE:
Published 18 Feb 2011 | info:doi/10.1371/journal.pone.0016765

A Multi-Functional Synthetic Gene Network: A Frequency Multiplier, Oscillator and Switch

Oliver Purcell, Mario di Bernardo, Claire S. Grierson, Nigel J. Savery

PLoS ONE:
Published 17 Feb 2011 | info:doi/10.1371/journal.pone.0016140

Self-Organization, Layered Structure, and Aggregation Enhance Persistence of a Synthetic Biofilm Consortium

Katie Brenner, Frances H. Arnold

PLoS ONE:
Published 09 Feb 2011 | info:doi/10.1371/journal.pone.0016791

Programmable Ligand Detection System in Plants through a Synthetic Signal Transduction Pathway

Mauricio S. Antunes, Kevin J. Morey, J. Jeff Smith, Kirk D. Albrecht, Tessa A. Bowen, Jeffrey K. Zdunek, Jared F. Troupe, Matthew J. Cuneo, Colleen T. Webb, Homme W. Hellinga, June I. Medford

PLoS ONE:
Published 25 Jan 2011 | info:doi/10.1371/journal.pone.0016292

De Novo Designed Proteins from a Library of Artificial Sequences Function inEscherichia Coli and Enable Cell Growth

Michael A. Fisher, Kara L. McKinley, Luke H. Bradley, Sara R. Viola, Michael H. Hecht

PLoS ONE:
Published 04 Jan 2011 | info:doi/10.1371/journal.pone.0015364

Characterization of Engineered Actin Binding Proteins That Control Filament Assembly and Structure

Crista M. Brawley, Serdar Uysal, Anthony A. Kossiakoff, Ronald S. Rock

PLoS ONE:
Published 12 Nov 2010 | info:doi/10.1371/journal.pone.0013960

Oscillations by Minimal Bacterial Suicide Circuits Reveal Hidden Facets of Host-Circuit Physiology

Philippe Marguet, Yu Tanouchi, Eric Spitz, Cameron Smith, Lingchong You

PLoS ONE:
Published 30 Jul 2010 | info:doi/10.1371/journal.pone.0011909

DMSO and Betaine Greatly Improve Amplification of GC-Rich Constructs in De Novo Synthesis

Michael A. Jensen, Marilyn Fukushima, Ronald W. Davis

PLoS ONE:
Published 11 Jun 2010 | info:doi/10.1371/journal.pone.0011024

An Environment-Sensitive Synthetic Microbial Ecosystem

Bo Hu, Jin Du, Rui-yang Zou, Ying-jin Yuan

PLoS ONE:
Published 12 May 2010 | info:doi/10.1371/journal.pone.0010619

Reverse Engineering of Bacterial Chemotaxis Pathway via Frequency Domain Analysis

Junjie Luo, Jun Wang, Ting Martin Ma, Zhirong Sun

PLoS ONE:
Published 09 Mar 2010 | info:doi/10.1371/journal.pone.0009182

Statecharts for Gene Network Modeling

Yong-Jun Shin, Mehrdad Nourani

PLoS ONE:
Published 23 Feb 2010 | info:doi/10.1371/journal.pone.0009376

An Engineered Yeast Efficiently Secreting Penicillin

Loknath Gidijala, Jan A. K. W. Kiel, Rutger D. Douma, Reza M. Seifar, Walter M. van Gulik, Roel A. L. Bovenberg, Marten Veenhuis, Ida J. van der Klei

PLoS ONE:
Published 15 Dec 2009 | info:doi/10.1371/journal.pone.0008317

How to Turn a Genetic Circuit into a Synthetic Tunable Oscillator, or a Bistable Switch

Lucia Marucci, David A. W. Barton, Irene Cantone, Maria Aurelia Ricci, Maria Pia Cosma, Stefania Santini, Diego di Bernardo, Mario di Bernardo

PLoS ONE:
Published 07 Dec 2009 | info:doi/10.1371/journal.pone.0008083

Gemini, a Bifunctional Enzymatic and Fluorescent Reporter of Gene Expression

Lance Martin, Austin Che, Drew Endy

PLoS ONE:
Published 04 Nov 2009 | info:doi/10.1371/journal.pone.0007569

A Man-Made ATP-Binding Protein Evolved Independent of Nature Causes Abnormal Growth in Bacterial Cells

Joshua M. Stomel, James W. Wilson, Megan A. León, Phillip Stafford, John C. Chaput

PLoS ONE:
Published 08 Oct 2009 | info:doi/10.1371/journal.pone.0007385

A Modified Consumer Inkjet for Spatiotemporal Control of Gene Expression

Daniel J. Cohen, Roberto C. Morfino, Michel M. Maharbiz

PLoS ONE:
Published 18 Sep 2009 | info:doi/10.1371/journal.pone.0007086

Design Parameters to Control Synthetic Gene Expression in Escherichia coli

Mark Welch, Sridhar Govindarajan, Jon E. Ness, Alan Villalobos, Austin Gurney, Jeremy Minshull, Claes Gustafsson

PLoS ONE:
Published 14 Sep 2009 | info:doi/10.1371/journal.pone.0007002

Synthetic Morphology Using Alternative Inputs

Hiromasa Tanaka, Tau-Mu Yi

PLoS ONE:
Published 10 Sep 2009 | info:doi/10.1371/journal.pone.0006946

Circular Polymerase Extension Cloning of Complex Gene Libraries and Pathways

Jiayuan Quan, Jingdong Tian

PLoS ONE:
Published 30 Jul 2009 | info:doi/10.1371/journal.pone.0006441

Golden Gate Shuffling: A One-Pot DNA Shuffling Method Based on Type IIs Restriction Enzymes

Carola Engler, Ramona Gruetzner, Romy Kandzia, Sylvestre Marillonnet

PLoS ONE:
Published 14 May 2009 | info:doi/10.1371/journal.pone.0005553

Monomeric Bistability and the Role of Autoloops in Gene Regulation

Stefanie Widder, Javier Macía, Ricard Solé

PLoS ONE:
Published 30 Apr 2009 | info:doi/10.1371/journal.pone.0005399

Timing Cellular Decision Making Under Noise via Cell–Cell Communication

Aneta Koseska, Alexey Zaikin, Jürgen Kurths, Jordi García-Ojalvo

PLoS ONE:
Published 13 Mar 2009 | info:doi/10.1371/journal.pone.0004872

High-Level Production of Amorpha-4,11-Diene, a Precursor of the Antimalarial Agent Artemisinin, in Escherichia coli

Hiroko Tsuruta, Christopher J. Paddon, Diana Eng, Jacob R. Lenihan, Tizita Horning, Larry C. Anthony, Rika Regentin, Jay D. Keasling, Neil S. Renninger, Jack D. Newman

PLoS ONE:
Published 16 Feb 2009 | info:doi/10.1371/journal.pone.0004489

Design and Construction of a Double Inversion Recombination Switch for Heritable Sequential Genetic Memory

Timothy S. Ham, Sung K. Lee, Jay D. Keasling, Adam P. Arkin

PLoS ONE:
Published 30 Jul 2008 | info:doi/10.1371/journal.pone.0002815

Targeted Development of Registries of Biological Parts

Jean Peccoud, Megan F. Blauvelt, Yizhi Cai, Kristal L. Cooper, Oswald Crasta, Emily C. DeLalla, Clive Evans, Otto Folkerts, Blair M. Lyons, Shrinivasrao P. Mane, Rebecca Shelton, Matthew A. Sweede, Sally A. Waldon

PLoS ONE:
Published 16 Jul 2008 | info:doi/10.1371/journal.pone.0002671

Bimodal and Hysteretic Expression in Mammalian Cells from a Synthetic Gene Circuit

Tobias May, Lee Eccleston, Sabrina Herrmann, Hansjörg Hauser, Jorge Goncalves, Dagmar Wirth

PLoS ONE:
Published 04 Jun 2008 | info:doi/10.1371/journal.pone.0002372

Synthetic Biology of Proteins: Tuning GFPs Folding and Stability with Fluoroproline

Thomas Steiner, Petra Hess, Jae Hyun Bae, Birgit Wiltschi, Luis Moroder, Nediljko Budisa

PLoS ONE:
Published 27 Feb 2008 | info:doi/10.1371/journal.pone.0001680

Reconstitution of Mdm2-Dependent Post-Translational Modifications of p53 in Yeast

Barbara Di Ventura, Charlotta Funaya, Claude Antony, Michael Knop, Luis Serrano

PLoS ONE:
Published 30 Jan 2008 | info:doi/10.1371/journal.pone.0001507

A Microfluidic Device for Temporally Controlled Gene Expression and Long-Term Fluorescent Imaging in Unperturbed Dividing Yeast Cells

Gilles Charvin, Frederick R. Cross, Eric D. Siggia

PLoS ONE:
Published 23 Jan 2008 | info:doi/10.1371/journal.pone.0001468

Printing Multistrain Bacterial Patterns with a Piezoelectric Inkjet Printer

Jack Merrin, Stanislas Leibler, John S. Chuang

PLoS ONE:
Published 25 Jul 2007 | info:doi/10.1371/journal.pone.0000663

High-Yield Hydrogen Production from Starch and Water by a Synthetic Enzymatic Pathway

Y.-H. Percival Zhang, Barbara R. Evans, Jonathan R. Mielenz, Robert C. Hopkins, Michael W.W. Adams

PLoS ONE:
Published 23 May 2007 | info:doi/10.1371/journal.pone.0000456

Designer Self-Assembling Peptide Nanofiber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional Cultures

Fabrizio Gelain, Daniele Bottai, Angleo Vescovi, Shuguang Zhang

PLoS ONE:
Published 27 Dec 2006 | info:doi/10.1371/journal.pone.0000119

Adaptive Response of a Gene Network to Environmental Changes by Fitness-Induced Attractor Selection

Akiko Kashiwagi, Itaru Urabe, Kunihiko Kaneko, Tetsuya Yomo

PLoS ONE:
Published 20 Dec 2006 | info:doi/10.1371/journal.pone.0000049

SOURCE

Read Full Post »

 

Tufts Health Plan to Cover Sequenom’s MaterniT21, Pathwork’s Tissue of Origin Tests

Reporter: Aviva Lev-Ari, PhD, RN

http://www.genomeweb.com/mdx/tufts-health-plan-cover-sequenoms-maternit21-pathworks-tissue-origin-tests

NEW YORK (GenomeWeb News) – Tufts Health Plan will begin covering Sequenom’s MaterniT21 Plus trisomy 21 test and Pathwork Diagnostics‘ Tissue of Origin test starting Oct. 1.

In an update to providers posted on its website, the health plan said that it may authorize coverage of the MaterniT21 test for patients who are plan members if they are at least 35 years old when they give birth; have a fetal aneuploidy screening test result including maternal serum screening and/or ultrasound evaluation that indicates the possibility of trisomy 21; or the plan member has a family history or prior pregnancy involving aneuploidy.

In a research note Oppenheimer analyst David Ferreiro said that Tufts Health Plan has approximately 1 million lives under coverage and a network of 90 hospitals and 25,000 healthcare providers.

“We view this decision as an incremental positive for [Sequenom] and as validation of the value proposition MaterniT21 presents to payors,” he said. “The adoption rate is encouraging and could positively impact payor decisions, further entrenching,” the company.

Two weeks ago, Sequenom said that in the second quarter revenues from its Sequenom Center for Molecular Medicine diagnostic services rose five-fold to $8.1 million driven by the MaterniT21 Plus test, which was launched in the fall. The test also detects for T18 and T13.

As adoption of the test continues to ramp at an increasing rate, the San Diego-based company increased its internal goal of billed MaterniT21 Plus tests for 2012 to 50,000 from an earlier goal of 40,000.

The company has stopped announcing coverage decisions by individual plans following an incident in the spring in which Coventry Health Care National Networkterminated a coverage decision for MaterniT21 Plus one week after Sequenom said that Coventy would cover the test. Sequenom said at the time that Coventry’s decision was without cause and was not a judgment on the company, Sequenom CMM, or its products.

In a statement today to GenomeWeb Daily News, a Sequenom spokesperson declined to disclose the terms of the contract with Tufts Health Plan. She said that Sequenom CMM has more than 26 million live under contract, and “we operate as an out-of-network laboratory where we are not yet contracted and bill payors accordingly.”

Tufts Health Plan also said that it will begin coverage of Pathwork Diagnostics’ Pathwork Tissue of Origin test, beginning on Oct. 1. The test is for the identification of challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers.

The plan said it may authorize coverage of the test if it is ordered by an oncologist and the plan member is diagnosed with metastatic cancer; the clinical evaluation has not identified the primary site of the cancer; the pathology report is submitted to Tufts Health Plan for review; and the pathology examination is unable to conclusively identify the primary site, or has identified two or more possible primary sites.

Use of the test to confirm a diagnosis will not be covered by the health plan.

 

 

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

Regulus Therapeutics and UC San Diego to Collaborate on Angiogenic Disease Research Utilizing microRNA Technology

http://www.fiercebiotech.com/press-releases/regulus-therapeutics-and-uc-san-diego-collaborate-angiogenic-disease-resear-0

– UC Discovery Grant award to support collaborative research –

La Jolla, Calif., April 14, 2011 – Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced it is collaborating with researchers at the University of California, San Diego (UCSD) School of Medicine seeking novel treatments for angiogenic diseases using microRNA therapeutics. The research will combine Regulus’ leading microRNA platform with UCSD’s expertise in animal models of angiogenesis to discover anti-angiogenic microRNA-targeted therapies that could be rapidly translated for treatment of human disease.  The collaborative research program was the recent recipient of a UC Discovery Grant that promotes collaborations between the university’s researchers and industry partners.  Financial terms of the grant were not disclosed.

“We are pleased to collaborate with leading scientific institutes like UCSD and to provide industry support for programs such as the UC Discovery Grant,” said Hubert C. Chen, M.D., Regulus’ vice president of translational medicine. “Regulus continues to demonstrate a leadership position in the field of microRNA therapeutics and is committed to forging partnerships with leading academic and clinical laboratories to advance microRNA biology and therapeutic discovery.  Our network of nearly 30 academic collaborations assists us with the investigation of new microRNAs and supports microRNA discovery efforts that feed the Company’s pipeline.”

Angiogenesis, which is the formation of new blood vessels, is an important event that contributes to the severity of cancer, diabetes, macular degeneration, inflammatory disease and arthritis.  microRNAs have been implicated in regulating biological networks involved in angiogenesis.

“Our research published last year in Nature Medicine demonstrated that microRNA-132 functions as a novel angiogenic switch that turns on angiogenesis in quiescent endothelial cells, and that targeting with an anti-miR-132 decreases blood vessel formation,” said David A. Cheresh, Ph.D., professor of pathology in the UCSD School of Medicine, associate director for translational research at UCSD Moores Cancer Center and principal investigator on the grant. “The objective of our collaborative work with Regulus is to advance these initial discoveries and discover additional microRNAs involved in angiogenic diseases.”

The UC Discovery Grant program promotes collaborations between the university’s researchers and industry partners in the interest of supporting cutting-edge research, strengthening the state’s economy and serving the public good.

About microRNAs

The discovery of microRNA in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 700 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs. A single microRNA can regulate entire networks of genes. As such, these molecules are considered master regulators of the human genome. microRNAs have been shown to play an integral role in numerous biological processes, including the immune response, cell-cycle control, metabolism, viral replication, stem cell differentiation and human development. Most microRNAs are conserved across multiple species, indicating the evolutionary importance of these molecules as modulators of critical biological pathways. Indeed, microRNA expression or function, has been shown to be significantly altered in many disease states, including cancer, heart failure and viral infections. Targeting microRNAs with anti-miRs, antisense oligonucleotide inhibitors of microRNAs, or miR-mimics, double-stranded oligonucleotides to replace microRNA function opens potential for a novel class of therapeutics and offers a unique approach to treating disease by modulating entire biological pathways. To learn more about microRNAs, please visit http://www.regulusrx.com/microrna/microrna-explained.php.

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years and tested in more than 5,000 humans. In addition, Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS). Regulus is advancing microRNA therapeutics towards the clinic in several key areas including hepatitis C infection, immuno-inflammatory diseases, fibrosis, oncology and cardiovascular/metabolic diseases. Regulus’ intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In April 2008, Regulus formed a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. In February 2010, Regulus and GlaxoSmithKline entered into a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of hepatitis C infection. In June 2010, Regulus and sanofi-aventis entered into the largest-to-date strategic alliance for the development of microRNA therapeutics. This alliance is focused initially on fibrosis. For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the future therapeutic and commercial potential of Regulus’ business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Any statement describing Regulus’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Such forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause the results to differ materially from those expressed or implied by such forward-looking statements. Although these forward-looking statements reflect the good faith judgment of Regulus’ management, these statements are based only on facts and factors currently known by Regulus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Regulus’ programs are described in additional detail in each of Alnylam’s and Isis’ annual report on Form 10-K for the year ended December 31, 2010, which are on file with the SEC. Copies of these and other documents are available from either Alnylam or Isis.

Read Full Post »

Author and Reporter: Anamika Sarkar, Ph.D.

Today, the gold standard treatment for cancer is still chemo therapy or radiation therapy. Drugs are administered to treat patients with different doses, frequencies and combinations. It is recognized that the side effects of all these therapies lead to DNA damage responses (DDR) and their subsequent signaling alterations resulting in cellular functions. Moreover, it is well known that DDR is responsible for complex cross talks and feedback of signaling pathways for progrowth and apoptosis within intracellular as well as extracellular networks (in tissues).

Optimal combinations of drugs in respect of doses or frequencies or order of treatments of different drugs have been recognized as a powerful method of treatment of complex diseases. However, executing experiments of multiple possible combinations of drugs and cell lines can easily lead to very costly proposition. Lee et.al in their paper published in Cell (2012), titled “Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks”, reported from experimental results that when triple negative breast cancer (TNBC) cells are treated, with a combination of drugs  – erlotinib, which is an EGFR inhibitor, at least 4 hours before of another drug, doxorubicin – the cells show higher apoptotic (cell death) responses. Other forms of treatments like, single administration of the drugs or treating the cells together with two drugs at same time, did not show any increased levels of apoptosis in TNBC cells.

They complemented their understanding of reason behind such unique behavior of TNBC cells, when exposed to time -stagger treatment of drugs, with systems level modeling. They used quantitative analysis of high throughput reverse-phase protein microarrays and quantitative western blotting of experiments. They chose to measure activation states of 35 signaling proteins at 12 time points following exposure to ertolinib and doxorubicin individually and in combinations. The authors used PLS (Partial Least Square) and PCA (Principle Component Analysis) methods for predictive analysis from data driven model.

They report from their systems level analysis that time – stagger treatment of TNBC with two drugs ertolinib and doxorubicin activate Caspase 8, a key apoptotic signaling component, which remains absent in other combinations of treatments of drugs. They hypothesized that early treatment of ertolinib, inhibits EGFR responses, which increases levels of activated Caspase 8 and gets amplified after getting exposed to the second drug doxorubicin.

Combination therapy in treating complicated diseases like cancer has many importance in making the dose and treatment efficient. However, due to complex nature of signaling pathways, it poses increasing amount of challenges. Lee et. al., address some of those challenges by bringing in synergistic collaborations among different fields – experiments and mathematical modeling, which is the future of drug development.

Sources:

http://www.ncbi.nlm.nih.gov/pubmed/22579283

Read Full Post »

Obstructive Coronary Artery Disease diagnosed by RNA levels of 23 genes – CardioDx, a Pioneer in the Field of Cardiovascular Genomic Diagnostics

Curator: Aviva Lev-Ari, PhD, RN

UPDATED on 11/15/2013

CardioDx, Inc. Nixes IPO, Cites Unfavorable Market Conditions

11/15/2013 10:31:01 AM

 

CardioDx postpones its initial public offering, citing ‘unfavorable market conditions.’ California molecular diagnostics company CardioDx spiked its initial public offering, citing “unfavorable market conditions,” according to news reports. The 5.8-million-share offering by Palo Alto-based CardioDx was slated to raise $92 million at a share price of $14-$16 apiece. The IPO, originally scheduled for yesterday, would have seen CardioDx shares trade under the “CDX” symbol.

SOURCE

http://www.devicespace.com/news_story.aspx?NewsEntityId=315972&type=email&source=DS_111513

CardioDx had planned to use some of the funds to expand its commercial efforts, including its sales and marketing workforce; to fund operations as the company pursues more insurance coverage and reimbursement; to “conduct additional clinical and marketing activities” for the company’s Corus CAD blood-based gene expression test; to fund R&D activity; and for “general corporate purposes.” CardioDx will later specify just the how much it plans to put toward each of those activities.

Investors in the company include V-Sciences Investments, Longitude Venture Partners, Artiman Ventures, Kleiner Perkins Caufield & Byers, JP Morgan and Mohr Davidow Ventures.

SOURCE

http://www.massdevice.com/news/cardiodx-spikes-ipo

CardioDX pulls IPO, citing poor market conditions

CardioDX, led by David Levison, was one of three medical technology companies to postpone their IPOs on Thursday due to poor market conditions.

Senior Technology Reporter-Silicon Valley Business Journal
CardioDX postponed an IPO on Thursday after deciding that the market is unfavorable at this time.

 

The Palo Alto company led by CEO David Levison was one of three planned medical tech companies that postponed going public on Thursday. San Diego-basedCelladon and Monrovia-based Xencor also decided to hold off due to poor market conditions.

Redwood City pharmaceutical developer Relypsa, meanwhile, went ahead with a drastically reduced IPO that raised about half of what it had been projected for it.

CardioDX, which sells diagnostic tests for cardiovascular disease, reported total revenue in in 2012 of $2.5 million and a net loss of $25.6 million. The company expects to continue to show losses for the next several years and has an accumulated deficit through June totaling $165.9 million. As of June 30, it had $46.8 million in cash, equivalents and investments.

The company’s biggest existing stakeholder is V-Sciences Investments, a wholly owned subsidiary of Temasek Life Sciences Private Ltd., which holds 19.9 percent of outstanding shares.

Other big stakeholders are Longitude Venture Partners, with a 17.9 percent stake; Artiman Ventures, 13.9 percent; Kleiner Perkins Caufield & Byers, 9.5 percent; JP Morgan, 6.4 percent; and Mohr Davidow Ventures, 5.8 percent.

SOURCE

http://www.bizjournals.com/sanjose/news/2013/11/15/cardiodx-pulls-ipo-citing-poor-market.html

Cardiovascular MDx Firm CardioDx Files to Go Public

UPDATED on 10/14/2013

October 14, 2013

NEW YORK (GenomeWeb News) – Cardiovascular molecular diagnostics firm CardioDx has filed with the US Securities and Exchange Commission to go public with an intended offering of up to $86.3 million of common stock.

The Palo Alto, Calif.-based firm has not priced its offering yet or said how many shares it plans on offering. Bank of America Merrill Lynch and Jefferies are listed as joint book-running managers on the offering, while Piper Jaffray and William Blair are co-managers.

The company plans on listing on the Nasdaq Global Market under ticker symbol “CDX.”

In its Form S-1, CardioDx said that its tests provide healthcare professionals with “critical, actionable information to improve patient care and management,” with an initial focus on coronary artery diseases (CAD), arrhythmia, and heart failure.

Its flagship product is the Corus CAD, a gene expression-based test for assessing non-diabetic patients who display symptoms suggestive of obstructive CAD. The test was launched in 2009 and through June 30, CardioDx delivered results for more than 40,000 tests, it said.

Corus CAD received Medicare Part B coverage in August 2012, making it a covered benefit for about 48 million Medicare beneficiaries, the company added.

In 2012, CardioDx posted $2.5 million in revenues with a net loss of $25.6 million. Through the first six months of 2013, the firm had revenues $2.9 million and a net loss of $18.4 million.

It had $46.8 million in cash, cash equivalents, and investments as of June 30, it said.

In August 2012, CardioDx raised $58 million in private financing. Before that, it raised $60 million in a financing round. In 2010, GE Healthcare invested $5 million in the company as part of a Series D financing round.

David Levison heads the firm as President and CEO. Other members of the management team include CFO Andrew Guggenhime; Chief Scientific Officer Steven Rosenberg; Chief Medical Officer Mark Monane; and Chief Commercial Officer Deborah Kilpatrick.

CardioDx is the latest in a recent string of omics-related companies who have gone public or have filed to go public in the US. Cancer GeneticsNanoString Technologies, and Foundation Medicine launched their IPOs earlier this year. Meanwhile, VeracyteBiocept, and Evogene have filed to float.

UPDATED on 2/25/2013

CardioDx Announces Publication of COMPASS Study Demonstrating the Corus CAD Test Outperforms Myocardial Perfusion Imaging in Overall Diagnostic Accuracy for Obstructive Coronary Artery Disease

February 24, 2013
CardioDx Announces Publication of COMPASS Study Demonstrating the Corus CAD Test Outperforms Myocardial Perfusion Imaging in Overall Diagnostic Accuracy for Obstructive Coronary Artery Disease

Tue Feb 19, 2013 8:30am EST

– Study Highlights the Validity of Corus CAD as a First-Line Test to Help Clinicians Exclude Obstructive CAD as a Cause of the Patient’s Symptoms – PALO ALTO, Calif.,  Feb. 19, 2013

/PRNewswire/ — CardioDx, Inc., a pioneer in the field of  cardiovascular genomic diagnostics, today announced the publication of the COMPASS (Coronary  Obstruction Detection by  Molecular
Personalized Gene Expression) study in  Circulation: Cardiovascular Genetics,  a journal of the American Heart Association. 

Results of the prospective, multi-center U.S. study showed that  Corus®  CAD, a blood-based  gene expression test, demonstrated high accuracy with both a high negative predictive value (96 percent) and high sensitivity (89 percent) for assessing  obstructive coronary artery disease  (CAD) in a population of patients referred for stress testing with myocardial perfusion imaging (MPI).  The study’s authors conclude that using Corus CAD earlier in the diagnostic algorithm could reduce the number of invasive cardiac tests by more accurately evaluating the presence of obstructive coronary artery disease compared to the traditional algorithm of stress myocardial perfusion imaging (MPI) in these patients.

COMPASS enrolled stable patients with symptoms suggestive of CAD who had been referred for MPI at 19 U.S. sites.  A blood sample was obtained in all 431 patients prior to MPI and Corus CAD gene expression testing was performed with study investigators blinded to Corus CAD test results. Following MPI, patients underwent either invasive coronary angiography or coronary CT angiography, gold-standard anatomical tests for the diagnosis of coronary artery disease. 

The study was designed to provide additional independent validation of the Corus CAD test in a real-world intended use patient population of patients presenting for MPI, a common noninvasive test for CAD, and builds on the results of the previous PREDICT validation study. Corus CAD requires only a simple blood draw for testing, making it safe, convenient, and easy to administer. The study evaluated results in stable non-diabetic patients with typical or atypical symptoms suggestive of CAD and found that Corus CAD surpassed the accuracy of MPI, a test that was administered more 10 million times in the U.S. in 2010.[1]

“The evaluation of stable patients with chest pain and other symptoms suggestive of CAD is a common challenge for clinicians, accounting for as many as 10,000 outpatient visits each day,” said the publication’s lead author,  Gregory S. Thomas, M.D., M.P.H., Medical Director of the MemorialCare Heart & Vascular Institute at Long Beach Memorial Medical Center and Clinical Professor of Medicine and Director of Nuclear Cardiology Education at the  University of California-Irvine  School of Medicine. “In the U.S., MPI testing is often performed in these patients and is followed by referral to invasive coronary angiography. Based on the results of this study of the Corus CAD gene expression test, we now have a reliable diagnostic approach for evaluating patients with symptoms of obstructive CAD.  With its high sensitivity and negative predictive value, Corus CAD may help clinicians accurately and efficiently exclude the diagnosis of obstructive CAD early in the diagnostic pathway, so they can assess for other causes of their patients’ symptoms.”

The pre-specified primary endpoint of the COMPASS study was the receiver-operator characteristics (ROC) analysis to evaluate the ability of Corus CAD to identify coronary arterial blockages of 50 percent or greater by quantitative coronary angiography.  Corus CAD outperformed MPI in overall diagnostic accuracy for assessing obstructive CAD, with an area under the curve (AUC) of 0.79 for the Corus CAD test compared to MPI site and core-lab read AUCs of 0.59 and 0.63 respectively (p<0.001).  In addition, Corus CAD performed better than MPI in sensitivity (89 percent vs. 27 percent, p<0.001) and negative predictive value (96 percent vs. 88 percent, p<0.001) parameters, thus demonstrating excellent performance for excluding obstructive CAD as the cause of a patient’s symptoms.  The COMPASS results corroborated earlier findings from the PREDICT multicenter U.S. validation study[2] demonstrating that the Corus CAD score is proportional to coronary artery stenosis severity.

“Corus CAD can help solve an enormous unmet need in healthcare by providing clinicians with a safe, convenient and reliable tool to help evaluate common patient symptoms and triage them more appropriately for subsequent therapy or additional testing,” said  David Levison, President and CEO of CardioDx.  “In addition to its higher diagnostic accuracy, Corus CAD holds potential to reduce a major healthcare expense category – unnecessary noninvasive imaging and/or invasive coronary angiography procedures and their associated risks and side effects. We have worked closely with leading clinicians to build a solid clinical and economic foundation for Corus CAD, leading to its growing acceptance in the medical and payer communities as evidenced by the more than 35,000 tests performed to date and Medicare’s decision to cover the test.”

 SOURCE:

http://www.fiercemedicaldevices.com/press-releases/cardiodx-announces-publication-compass-study-demonstrating-corus-cad-test-o

CardioDx is promoting yet another post-marketing study whose data may help the company’s gene expression test for obstructive coronary artery disease reach more patients, better compete with the standard of care and also build vital market share.

Executives at the California-based 2012 Fierce 15 company say they wanted more data on Corus CAD‘s real-world use, building on its previous PREDICT validation trial as a result. The test has been on sale commercially since 2009 and won crucial Medicare reimbursement last fall. Chief Scientific Officer Steven Rosenberg told FierceMedicalDevices via email that the results from the latest study pointed in a number of positive directions.

“It demonstrates performance at least as good as that seen in the PREDICT study, but in the population the Corus CAD is indicated for,” Rosenberg said, “It shows significantly higher performance for obstructive CAD than MPI, which is the most common non-invasive imaging test used in this regard.”

A 431-patient clinical study of the blood diagnostic rated the test with a 96% negative predictive value and 89% high sensitivity, in assessing the condition in patients who were referred for stress testing with myocardial perfusion imaging (MPI). (Last November, CardioDx heralded similar results from another study using Corus CAD on 98 geriatric patients.) Details are published in the journal Circulation: Cardiovascular Genetics.

The blood test, conducted at 19 U.S. sites through multiple academic institutions, determined that using Corus CAD earlier in the diagnostic process better assessed the presence of coronary artery disease versus MPI. This might encourage doctors to cut back on invasive, more expensive cardiac tests by ruling out obstructive CAD sooner. In other words, determining a patient doesn’t have obstructive CAD eliminates the need for diagnostic procedures such as coronary angiography or coronary CT angiography, the company explains.

Post-marketing studies are increasingly important in today’s health care market, with the need to demonstrate the utility of a device or diagnostic in as most detailed a way possible. And it’s not just boosting the standard of care; the Affordable Care Act means value matters, too, more than ever before. Success with this mission can help broaden market share and also increase the chance of private as well as government insurance coverage. Additionally, new post-marketing trials can also set the stage for expanded indications down the line.

SOURCE:

http://www.fiercemedicaldevices.com/story/cardiodx-cad-dx-passes-another-post-marketing-test/2013-02-24?utm_medium=nl&utm_source=internal

A Blood Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Non-Diabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study

  1. Gregory S. Thomas1*,
  2. Szilard Voros2,
  3. John A. McPherson3,
  4. Alexandra J. Lansky4,
  5. Mary E. Winn5,
  6. Timothy M. Bateman6,
  7. Michael R. Elashoff7,
  8. Hsiao D. Lieu7,
  9. Andrea M. Johnson7,
  10. Susan E. Daniels7,
  11. Joseph A. Ladapo8,
  12. Charles E. Phelps9,
  13. Pamela S. Douglas10 and
  14. Steven Rosenberg7

+Author Affiliations


  1. 1Long Beach Memorial Medical Center, Long Beach & University of California, Irvine, CA

  2. 2Stony Brook University Medical Center, Stony Brook, NY

  3. 3Vanderbilt University, Nashville, TN

  4. 4Yale University School of Medicine, New Haven, CN

  5. 5Scripps Translational Science Institute, La Jolla, CA

  6. 6University of Missouri, Kansas City, MO

  7. 7CardioDx, Inc., Palo Alto, CA

  8. 8New York University School of Medicine, New York, NY

  9. 9University of Rochester, Rochester, NY

  10. 10Duke Clinical Research Institute, Duke University, Durham, NC
  1. * MemorialCare Heart and Vascular Institute, Long Beach Memorial Medical Center, 2801 Atlantic Avenue, Long Beach, CA 90806 gthomas@mimg.com

Abstract

Background—Obstructive coronary artery disease (CAD) diagnosis in symptomatic patients often involves non-invasive testing before invasive coronary angiography (ICA). A blood-based gene expression score (GES) was previously validated in non-diabetic patients referred for ICA but not in symptomatic patients referred for myocardial perfusion imaging (MPI).

Methods and Results—This prospective multi-center study obtained peripheral blood samples for GES before MPI in 537 consecutive patients. Patients with abnormal MPI usually underwent ICA; all others had research coronary CT-angiography (CTA), with core laboratories defining coronary anatomy. A total of 431 patients completed GES, coronary imaging (ICA or CTA), and MPI. Mean age was 56±10 (48% women). The pre-specified primary endpoint was GES receiver-operator characteristics (ROC) analysis to discriminate ≥50% stenosis (15% prevalence by core laboratory analysis). ROC curve area (AUC) for GES was 0.79 (95% CI 0.73-0.84, p<.001), with sensitivity, specificity, and negative predictive value (NPV) of 89%, 52%, and 96%, respectively, at a pre-specified threshold of ≤15 with 46% of patients below this score. The GES outperformed clinical factors by ROC and reclassification analysis and also showed significant correlation with maximum percent stenosis. Six-month follow-up on 97% of patients showed that 27/28 patients with adverse cardiovascular events or revascularization had GES >15. Site and core-lab MPI had AUCs of 0.59 and 0.63, respectively, significantly less than GES.

ConclusionsA GES has high sensitivity and NPV for obstructive CAD. In this population clinically referred for MPI, the GES outperformed clinical factors and MPI.

Clinical Trial Registration Information—www.clinicaltrials.gov; Identifier: NCT01117506.

  • Received June 6, 2012.
  • Revision received January 15, 2013.
  • Accepted February 5, 2013.

http://circgenetics.ahajournals.org/content/early/2013/02/15/CIRCGENETICS.112.964015.abstract?sid=74741525-8453-460e-8407-f11022fe9a24

http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/08/cardiodx-corus-medicare-heart-disease.html

CardioDx heart disease test wins Medicare coverage

San Francisco Business Times by Ron Leuty, Reporter

Date: Wednesday, August 8, 2012, 4:00am PDT

CardioDx's test for obstructive heart disease will be covered by Medicare retroactive to Jan. 1.
Photo supplied by CardioDx

CardioDx’s test for obstructive heart disease will be covered by Medicare retroactive to Jan. 1.

Reporter- San Francisco Business Times
 

A key national Medicare contractor will cover the cost of a coronary artery disease test developed by CardioDx Inc.

The move is important for Palo Alto-based CardioDx because private insurers tend to follow the federal government’s Medicare health insurance program. The company has had to seek reimbursement on a case-by-case basis with those private insurers since its Corus CAD gene expression test hit the market in June 2009.

The decision disclosed Tuesday by Palmetto GBA, a national contractor that administers Medicare benefits in Columbia, S.C., means that Medicare will cover the test for as many as 40 million enrollees. Coverage is retroactive to Jan. 1.

Corus CAD is a shoebox-size kit that uses a simple blood draw to measure the RNA levels of 23 genes. Using an algorithm, it then creates a score that determines the likelihood that a patient has obstructive coronary artery disease.

“By providing Medicare beneficiaries access to Corus CAD, this coverage decision enables patients to avoid unnecessary procedures and risks associated with cardiac imaging and elective invasive angiography, while helping payers address an area of significant healthcare spending,” CardioDx President and CEO David Levison said in a press release.

The decision represents the latest Medicare-coverage win for Bay Area diagnostic test makers. Palmetto earlier this year opted to cover the Afirma gene expression test from South San Francisco’s Veracyte Inc. to diagnosis thyroid nodules, and last summer Palmetto said it would cover Redwood City-based Genomic Health Inc.’s (NASDAQ: GHDX)colon cancer recurrence test.

Read Full Post »

Author and Reporter: Ritu Saxena, Ph.D.

On 5th of July, I  discussed a general overview of varied mitochondrial functions, diseases, diagnosis and the current research focused on treatment of mitochondrial diseases in a post titled “Mitochondria: More than just the powerhouse of the cell”. http://pharmaceuticalintelligence.com/2012/07/09/mitochondria-more-than-just-the-powerhouse-of-the-cell/

Current post talks about a new technique that has been introduced by the authors as a ‘Comprehensive 1-Step Molecular Analyses of Mitochondrial Genome by Massively Parallel Sequencing’. The technique was recently published in the Clinical Chemistry journal (2012) by Zhang et al.

One mitochondria may have multiple copies of mtDNA  and an interesting feature observed in mitochondria is the heteroplasmy, a phenomenon where mutant and wild-type mtDNA can co-exist. During cell division, the mutant and wild-type copies are distributed randomly in daughter cells. The impact is in the heterogeneity with respect to penetrance and expressivity along that has diverse manifestations in terms of organs being affected, age of onset and the rate of progression. With such variability, the diagnosis becomes even more challenging. Therefore, mutational analysis along with accurate heteroplasmy detection in the mtDNA is an important part of the diagnosis. Thus, there is need for accurate and faster mutation detection methods for patients that are suspected to carry a mitochondrial disease.

The current molecular diagnostic methods for the detection of mtDNA mutations involves several different and complimentary methods. The detection of mutations is approached by first screening for a panel of point mutations that have been commonly associated with the mitochondrial diseases, followed by the quantification of the mutant load. In case none of the point mutations show up in the screening, the whole genome sequencing of mtDNA is performed to identify rare or novel mutations that might be associated with the disease. Also, in order to analyze large deletions within the genome, a an additional step of Southern blotting needs to be performed. Zhang et al, however, developed a novel approach to analyze the mtDNA in “single” step.

The method employed for the 1-step technique is to first enrich the entire mtDNA using amplification by PCR followed by massively parallel sequencing to detect point mutations as well as large heteroplasmic deletions simultaneously. A total of 45 samples were analyzed for the evaluation of analytic sensitivity and specificity. As stated by the authors “Our analysis demonstrated 100% diagnostic sensitivity and specificity of base calls compared to the results from Sanger sequencing” and added ” the method also detected large deletions with the breakpoints mapped”. Apart from the fact that the 1-step technique is less complex, the detection of point mutations has been found to be more accurate compared to Sanger sequencing that doesn’t provide any quantitative information and falls short of detecting heteroplasmy lying below 15%.

Thus,  the 1-step technique developed by Zhang et al has been demonstrated to be better than the combination of methods currently utilized for the detection of mtDNA mutations in terms of simplicity, cost effectiveness and accuracy.

Sources:

http://www.ncbi.nlm.nih.gov/pubmed?term=Comprehensive%201-Step%20Molecular%20Analyses%20of%20Mitochondrial%20Genome%20by%20Massively%20Parallel%20Sequencing

http://pharmaceuticalintelligence.com/2012/07/09/mitochondria-more-than-just-the-powerhouse-of-the-cell/

Read Full Post »

« Newer Posts - Older Posts »